<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="pediatricmusic/PMC4244172/results/search/disease/results.xml">
  <result pre="http://www.uk.sagepub.com/aboutus/openaccess.htm). Caregivers, employment, and healthcare utilization P001 Caregiver’s burden in" exact="multiple sclerosis" post="is higher in Mexican population R Llorens-Arenas 1, L"/>
  <result pre="are no studies addressing the issue in Mexican caregivers of" exact="multiple sclerosis" post="patients. Objectives: To describe the prevalence and predicting factors"/>
  <result pre="describe the prevalence and predicting factors of caregiver burden in" exact="multiple sclerosis" post="within a Mexican population. Methods: 99 Caregiver-patient pairs were"/>
  <result pre="even 5 years before diagnosis. P003 Knowledge and attitude towards" exact="multiple sclerosis" post="in Turkey S Canbaz Kabay 1,2, H Ozışık Karaman"/>
  <result pre="Turkey, in an eastern city Kütahya. Methods: The Survey of" exact="multiple sclerosis" post="patients, their relatives and control group on the Knowledge,"/>
  <result pre="of working capability in a Swiss cohort of patients with" exact="multiple sclerosis" post="O Findling 1, M Baltisberger 1, CP Kamm 1,"/>
  <result pre="München, Neurology, München, Germany Background: Diagnosis and disability associated with" exact="multiple sclerosis" post="(MS) have far reaching implications on the patient’s private"/>
  <result pre="education-related inequalities are warranted. P005 Profile of social participation of" exact="multiple sclerosis" post="adults in Québec city N Lacroix 1,2, N Boucher"/>
  <result pre="physical and psychological consequences of chronic degenerative diseases such as" exact="multiple sclerosis" post="(MS). Only a few studies have focused on the"/>
  <result pre="roles. P006 Determinants of stigma experienced by patients suffering from" exact="multiple sclerosis." post="A Hellenic population study M Anagnostouli 1, S Katsavos"/>
  <result pre="and Society, Division of Nursing, Huddinge, Sweden Background: People with" exact="multiple sclerosis" post="(PwMS) use a large amount of health care services"/>
  <result pre="University Hospital, Neurology, Rennes, France Background: Introducing oral treatment for" exact="multiple sclerosis" post="(MS) relapses should improve its accessibility, patients quality of"/>
  <result pre="mg twice daily, for improvement in walking in patients with" exact="multiple sclerosis" post="(MS). Objectives: To describe patient characteristics and to evaluate"/>
  <result pre="prior claims for stroke, Parkinson’s disease, brain neoplasm/abscess, tendonitis, or" exact="cerebral palsy." post="Demographics and comorbidities were assessed at baseline. Patients were"/>
  <result pre="approved in over 30 countries for the treatment of relapsing-remitting" exact="multiple sclerosis" post="(RRMS). In the phase 3 CARE-MS II study, alemtuzumab"/>
  <result pre="is approved in over 30 countries for treatment of relapsing-remitting" exact="multiple sclerosis" post="(RRMS). Alemtuzumab demonstrated superior efficacy over subcutaneous interferon beta-1a"/>
  <result pre="Swedish social redistribution systems. P015 Prevalence of complications in hospitalized" exact="multiple sclerosis" post="patients among different age groups: national perspective AA Patel"/>
  <result pre="Lansing, MI, United States Background: Multiple Sclerosis (MS) is a" exact="neurological disorder" post="without any clinical findings that are unique to MS."/>
  <result pre="is national representative of 1,393,298 (weighted) patients. Overall prevalence of" exact="optic neuritis" post="(1.6%), urinary tract infection (UTI)(25.2%), unspecified hypertension (HTN)(30.2%), aspiration"/>
  <result pre="of 1,393,298 (weighted) patients. Overall prevalence of optic neuritis (1.6%)," exact="urinary tract infection" post="(UTI)(25.2%), unspecified hypertension (HTN)(30.2%), aspiration pneumonia(3.6%), depressive disorder (14.1%),"/>
  <result pre="infection (UTI)(25.2%), unspecified hypertension (HTN)(30.2%), aspiration pneumonia(3.6%), depressive disorder (14.1%)," exact="neurogenic bladder" post="(10.6%), septicemia(10.1%), epilepsy(3.6%). After age groups stratification prevalence of"/>
  <result pre="bladder (10.6%), septicemia(10.1%), epilepsy(3.6%). After age groups stratification prevalence of" exact="optic neuritis" post="was highest (11.5%) in 0-18 age group and was"/>
  <result pre="with increasing age (p&amp;lt; 0.001). Prevalence of UTI, HTN and" exact="aspiration pneumonia" post="were increasing with age being highest (35.2%, 43.3% and"/>
  <result pre="increasing age (p&amp;lt; 0.001). Prevalence of UTI, HTN and aspiration" exact="pneumonia" post="were increasing with age being highest (35.2%, 43.3% and"/>
  <result pre="50-59 and then declining with age (p&amp;lt; 0.001). Prevalence of" exact="neurogenic bladder" post="and septicemia were increasing with age being highest (13.4%"/>
  <result pre="then decreased in age group &amp;gt;70 (p&amp;lt; 0.001). Prevalence of" exact="epilepsy" post="was also increasing with age being highest (4.1%) in"/>
  <result pre="patients is highly variable in different age groups. Prevalence of" exact="optic neuritis" post="and epilepsy were more in younger patients of MS"/>
  <result pre="variable in different age groups. Prevalence of optic neuritis and" exact="epilepsy" post="were more in younger patients of MS while other"/>
  <result pre="more in younger patients of MS while other complications like" exact="neurogenic bladder," post="UTIs, aspiration pneumonia, septicemia and depressive disorder were higher"/>
  <result pre="patients of MS while other complications like neurogenic bladder, UTIs," exact="aspiration pneumonia," post="septicemia and depressive disorder were higher in old age"/>
  <result pre="and atrophy are associated with employment status in patients with" exact="multiple sclerosis" post="S Tauhid 1, R Chu 1, R Sasane 2,"/>
  <result pre="ability to perform occupational functions is a common difficulty for" exact="multiple sclerosis" post="(MS) patients. This impaired level of performance can frequently"/>
  <result pre="hypointensity is most relevant. P017 Treatment patterns and cost in" exact="multiple sclerosis" post="- a cross-sectional study from Slovakia V Donath 1,"/>
  <result pre="2013), as well as estimate the long term cost of" exact="multiple sclerosis" post="to patients in Norway. Methods: Information on disease related"/>
  <result pre="patients with MS. P020 Updates from the Sonya Slifka longitudinal" exact="multiple sclerosis" post="study and the comprehensive analysis of the direct and"/>
  <result pre="among a generally representative sample of almost 2,200 individuals with" exact="multiple sclerosis" post="(MS) in the United States (US). A second cohort"/>
  <result pre="efficient healthcare resources allocation. P022 The economic cost of a" exact="multiple sclerosis" post="relapse K O’Connell 1, SB Kelly 1, E Fogarty"/>
  <result pre="of MS patients regardless of disease severity. P024 People with" exact="multiple sclerosis" post="unmet perceived needs point toward a personalised intervention M"/>
  <result pre="Medicine and Public Health, Siena, Italy Background: The effects of" exact="multiple sclerosis" post="(MS) are wide-ranging, having an impact on physical, psychological,"/>
  <result pre="Idiopathic Inflammatory Demyelinating Central Nervous System Disorders (IIDCDs) such as" exact="neuromyelitis optica" post="(NMO) and multiple sclerosis (MS) causes higher prevalence of"/>
  <result pre="Nervous System Disorders (IIDCDs) such as neuromyelitis optica (NMO) and" exact="multiple sclerosis" post="(MS) causes higher prevalence of the diseases over the"/>
  <result pre="and emergency room visits in the US among patients with" exact="multiple sclerosis" post="A Farr 1, S Curkendall 2, E Yu 3,"/>
  <result pre="3Genentech, San Francisco, CA, United States Background: Among patients with" exact="multiple sclerosis" post="(MS), few studies have examined the association between persistence"/>
  <result pre="the prevalence and characteristics of medicare patients using treatments for" exact="multiple sclerosis" post="and related symptoms in the USA S Chahin 1,"/>
  <result pre="is a non-interventional study in 1705 patients with relapsing remitting" exact="multiple sclerosis" post="(RRMS). PEARL collected pharmacoeconomic and clinical data for 24"/>
  <result pre="on healthcare resource utilization and medical costs for patients with" exact="multiple sclerosis" post="S Yermakov 1, M Davis 1, M Calnan 1,"/>
  <result pre="disease modifying therapy (DMT) is suboptimal in many patients with" exact="multiple sclerosis" post="(MS). Prior studies have shown MS patients with high"/>
  <result pre="explore the appropriateness of current and emerging treatments for relapsing-remitting" exact="multiple sclerosis" post="HJ Stoevelaar 1, F Barkhof 2, T Berger 3,"/>
  <result pre="Dresden, Germany Background: The therapeutic arsenal for patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS) is rapidly expanding. Over the last few years,"/>
  <result pre="the study of quality of life (QoL) in patients with" exact="multiple sclerosis" post="(MS). However the study of QoL and well-being in"/>
  <result pre="tests to monitor disease activity among patients with relapsing remitting" exact="multiple sclerosis" post="in the United States and Europe P O’Meara 1,"/>
  <result pre="a validation tool for fine-grained measures of motor dysfunction in" exact="multiple sclerosis" post="J Burggraaff 1, M D’Souza 2, J Dorn 3,"/>
  <result pre="For a more reliable and sensitive assessment of disability in" exact="multiple sclerosis" post="(MS) we are developing the ASSESS-MS system, which relies"/>
  <result pre="Scale (EDSS) is the most widely used disability-rating scale in" exact="multiple sclerosis" post="(MS), but has been criticized for its low reliability."/>
  <result pre="Infrared depth sensor based automated classification of motor dysfunction in" exact="multiple sclerosis" post="- a proof-of-concept study M D’Souza 1, J Burggraaf"/>
  <result pre="is the most frequently used scale to rate disability in" exact="multiple sclerosis" post="(MS) and an important outcome measure in clinical trials"/>
  <result pre="The squares test as a measure of hand function in" exact="multiple sclerosis" post="J Gielen 1, J Laton 1, J Van Schependom"/>
  <result pre="upper extremity function using the manual dexterity component of the" exact="multiple sclerosis" post="performance test: validation of novel metrics F Bethoux 1,"/>
  <result pre="of upper extremity (UE) function is a frequent consequence of" exact="multiple sclerosis" post="(MS). The MS Performance Test (MSPT) is an Ipad"/>
  <result pre="across subgroups with alemtuzumab versus interferon beta-1a in treatment-naive relapsing-remitting" exact="multiple sclerosis" post="X Montalban 1, DL Arnold 2,3, E Fisher 4,"/>
  <result pre="CARE-MS I (NCT00530348) trial in treatment-naive patients with active relapsing-remitting" exact="multiple sclerosis" post="(RRMS), alemtuzumab proved superior to subcutaneous interferon beta-1a (SC"/>
  <result pre="across various subgroups. P040 MRI outcomes in patients with early" exact="multiple sclerosis" post="treated with teriflunomide: subgroup analyses from the TOPIC phase"/>
  <result pre="Background: Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting" exact="multiple sclerosis" post="(MS). TOPIC (NCT00622700) is a phase 3 study that"/>
  <result pre="improve recovery following relapses: data from the 2-year ADVANCE relapsing-remitting" exact="multiple sclerosis" post="study BC Kieseier 1, TF Scott 2,3, SD Newsome"/>
  <result pre="in risk of sustained disability progression (SDP) observed in relapsing-remitting" exact="multiple sclerosis" post="(RRMS) patients treated with subcutaneous peginterferon beta-1a (PEG-IFN; 125"/>
  <result pre="Background: Alemtuzumab is approved in over 30 countries for relapsing-remitting" exact="multiple sclerosis" post="(RRMS). The phase 3 CARE-MS II study in patients"/>
  <result pre="other therapies. P044 Alemtuzumab improves quality of life in relapsing-remitting" exact="multiple sclerosis" post="patients who relapsed on prior therapy: 3-year follow-up of"/>
  <result pre="approved in over 30 countries for the treatment of relapsing-remitting" exact="multiple sclerosis" post="(RRMS). In CARE-MS II (NCT00548405), alemtuzumab had superior efficacy"/>
  <result pre="Background: Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting" exact="multiple sclerosis" post="(MS). The TEMSO (NCT00134563) and TOWER (NCT00751881) phase 3"/>
  <result pre="Background: Analysis of brain volume (BV) in patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS) in fingolimod clinical trials revealed relationships between variables"/>
  <result pre="a dose-ranging study of subcutaneous ofatumumab in subjects with relapsing-remitting" exact="multiple sclerosis" post="PS Sorenson 1, ST Kavanagh 2, DJ Austin 3,"/>
  <result pre="demonstrated the benefits of anti-CD20 monoclonal antibody treatments in relapsing-remitting" exact="multiple sclerosis" post="(RRMS). This study investigated the safety and efficacy of"/>
  <result pre="activity. Objectives: To assess subject safety, persistence of MRI lesion" exact="suppression" post="and B-cell repletion over the course of a 24-week"/>
  <result pre="SAE reported by more than one subject; no cases of" exact="progressive multifocal leukoencephalopathy" post="or opportunistic infections were observed. Assessment of efficacy data"/>
  <result pre="observed. Assessment of efficacy data showed that the MRI lesion" exact="suppression" post="seen during the 24-week treatment phase persisted through week"/>
  <result pre="P049 Safety, tolerability and efficacy of Boswellic acids in relapsing-remitting" exact="multiple sclerosis" post="- the SABA proof-of-concept trial KH Stürner 1, J-P"/>
  <result pre="to exhibit anti-inflammatory activities. Clinical trials with frankincense extracts in" exact="rheumatoid arthritis" post="showed very good tolerability and good efficacy in restraining"/>
  <result pre="exhibit anti-inflammatory activities. Clinical trials with frankincense extracts in rheumatoid" exact="arthritis" post="showed very good tolerability and good efficacy in restraining"/>
  <result pre="(S1P)-1,5 modulator, being developed for the treatment of secondary progressive" exact="multiple sclerosis" post="(MS). The therapeutic effects include prevention of circulating effector"/>
  <result pre="HYP 150mg once-monthly compared with placebo in patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS). Objectives: To determine the impact of DAC HYP"/>
  <result pre="Delayed-release dimethyl fumarate (DMF) demonstrated efficacy and safety in relapsing-remitting" exact="multiple sclerosis" post="in Phase 3 studies. Gastrointestinal (GI) events were common"/>
  <result pre="GI events. The incidences of flatulence (38.6% vs 50.6%) and" exact="diarrhea" post="(36.4% vs 48.2%) were lower in the bismuth subsalicylate"/>
  <result pre="1.8; LS mean difference [95% CI]: 0.7 [0.1, 1.3]) and" exact="diarrhea" post="(1.0 vs 1.6; LS mean difference [95% CI]: 0.6"/>
  <result pre="for flatulence (severe, 1.1% vs 5.9%; extreme, 0% vs 0%)," exact="diarrhea" post="(severe, 1.1% vs 9.4%; extreme, 0% vs 0%), upper"/>
  <result pre="on fatigue and quality of life measures in relapsing remitting" exact="multiple sclerosis" post="(MS) patients. Methods: We conducted a randomized-controlled, rater-blinded, 1-year"/>
  <result pre="oral L-carnitine versus placebo for the treatment of fatigue in" exact="multiple sclerosis" post="J-C Ouallet 1, D Laplaud 2, S Wiertlewski 2,"/>
  <result pre="supplementation. P057 Delayed-release dimethyl fumarate and disability assessed by the" exact="multiple sclerosis" post="functional composite: integrated analysis of DEFINE and CONFIRM G"/>
  <result pre="measures and an acceptable safety profile in patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS) in the Phase 3 DEFINE and CONFIRM studies."/>
  <result pre="oral immunomodulator approved for the treatment of patients with relapsing-remitting" exact="multiple sclerosis" post="(MS). The teriflunomide clinical development program includes four monotherapy"/>
  <result pre="fumarate (DMF) demonstrated efficacy and safety in patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS) in the 2-year, Phase 3 DEFINE and CONFIRM"/>
  <result pre="Background: Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting" exact="multiple sclerosis" post="(MS). Teriflunomide is known to decrease the proliferation of"/>
  <result pre="7 mg), and one (0.1%; placebo) patients discontinued due to" exact="neutropenia" post="or neutrophil count decrease as per the protocol requirement."/>
  <result pre="P062 Clinical efficacy of laquinimod 0.6mg once-daily in worsening relapsing-remitting" exact="multiple sclerosis" post="defined by baseline EDSS over 3 TL Vollmer 1,"/>
  <result pre="Neuro-Oncologie et Neuro-Inflammation, Lyon, France Background: Women are affected by" exact="multiple sclerosis" post="(MS) mainly in their childbearing years and the risk"/>
  <result pre="CONFIRM studies across a broad range of patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS). ENDORSE is an ongoing, 5-year, dose-blind extension study"/>
  <result pre="DMF on annualized relapse rate (ARR) in patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS) from DEFINE and CONFIRM who had received prior"/>
  <result pre="delayed-release dimethyl fumarate (DMF) was demonstrated in patients with relapsing−remitting" exact="multiple sclerosis" post="(RRMS) in the Phase 3 DEFINE and CONFIRM studies."/>
  <result pre="Year 1 of the Phase 3 ADVANCE study in relapsing-remitting" exact="multiple sclerosis" post="(RRMS), with a safety profile reflecting that of established"/>
  <result pre="LAQ had a more pronounced effect on indices of underlying" exact="neurodegeneration" post="(CDP, brain tissue loss) than on markers of acute"/>
  <result pre="effect on disability reduction is explained by mechanisms other than" exact="suppression" post="of acute inflammation. LAQ appears to have a different"/>
  <result pre="action of laquinimod and the onset of its activity in" exact="multiple sclerosis" post="(MS) patients are currently unknown. When 0.6mg of laquinimod"/>
  <result pre="erythropoietin on clinical disability and MRI in patients with progressive" exact="multiple sclerosis" post="KI Schreiber 1, M Magyari 1, FT Sellebjerg 1,"/>
  <result pre="weeks over placebo at 1 year in patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS; n=1512). Objectives: To explore the influence of treatment"/>
  <result pre="3 CARE-MS II trial (NCT00548405) in patients with active relapsing-remitting" exact="multiple sclerosis" post="(RRMS) who relapsed on prior therapy, alemtuzumab was superior"/>
  <result pre="Delayed-release dimethyl fumarate (DMF) demonstrated efficacy and safety in relapsing-remitting" exact="multiple sclerosis" post="in placebo-controlled clinical trials, including a Phase 2b trial"/>
  <result pre="a once-daily oral immunomodulator approved for the treatment of relapsing-remitting" exact="multiple sclerosis" post="(MS). Phase 3 studies of teriflunomide in patients with"/>
  <result pre="is a once-daily oral immunomodulator for the treatment of relapsing-remitting" exact="multiple sclerosis" post="(MS). In phase 2 and 3 studies, teriflunomide had"/>
  <result pre="randomized, double-blind, placebo-controlled phase IIa study of alpha B-crystallin in" exact="multiple sclerosis" post="JM van Noort 1, M Bsibsi 1, PJ Nacken"/>
  <result pre="1, EH Venneker 1 1Delta Crystallon, Leiden, Netherlands Background: During" exact="multiple sclerosis" post="(MS), widespread accumulation occurs of the small heat shock"/>
  <result pre="we identified a dose of HspB5 that led to significant" exact="suppression" post="of HspB5-specific memory T cell responses. Objectives: In this"/>
  <result pre="was the first oral therapy approved for treatment of relapsing-remitting" exact="multiple sclerosis" post="(RRMS). Between EMA approval and fingolimod availability on the"/>
  <result pre="systemic infections, history or presence of malignancy, uncontrolled diabetes or" exact="diabetic retinopathy," post="macular edema (ME), severe cardiovascular (CV) disease. Safety and"/>
  <result pre="history or presence of malignancy, uncontrolled diabetes or diabetic retinopathy," exact="macular edema" post="(ME), severe cardiovascular (CV) disease. Safety and tolerability of"/>
  <result pre="in 35.4% of patients, the most frequent being headache (4.1%)," exact="influenza" post="(2.1%), lymphopenia (1.8%), asthenia (1.8%) and pyrexia (1.8%). 18/906"/>
  <result pre="patients had a self-limiting CV AE (including 2 cases of" exact="atrioventricular block" post="- AVB- second degree Mobitz type I) with onset"/>
  <result pre="type I, 1 case of pneumonia, 1 case of acute" exact="respiratory failure," post="1 case of transaminase increase and 1 case of"/>
  <result pre="vitamin D deficiency to both susceptibility to, and severity of," exact="multiple sclerosis." post="We report the dose- response results in a sub-group"/>
  <result pre="efficacy over placebo at 1 year in patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS; n=1512). 1332 (88%) participants completed Year 1 of"/>
  <result pre="the previous pivotal multicenter trials. P087 Vitamin D levels in" exact="multiple sclerosis" post="in correlation to age, sex, EDSS and dosage of"/>
  <result pre="1 1Marianne Strauss Klinik, Berg, Germany Background: Vitamin D in" exact="multiple sclerosis" post="(MS) is still controversial discussed regarding the impact of"/>
  <result pre="reduces disease activity in treatment-naive patients with highly active relapsing-remitting" exact="multiple sclerosis" post="S Krieger 1, C Lubetzki 2, J Palmer 3,"/>
  <result pre="(65.7 vs 42.6%), thyroid events (13.3 vs 9.8%), and immune" exact="thrombocytopenia" post="(ITP; 1.9 vs 0%). Two alemtuzumab patients had grade"/>
  <result pre="Background: Alemtuzumab is approved in over 30 countries for relapsing-remitting" exact="multiple sclerosis" post="(RRMS). The phase 3 CARE-MS I study in treatment-naive"/>
  <result pre="and remained in the study. P091 Attitudes of people with" exact="multiple sclerosis" post="towards clinical research S Jordan 1, K O’Connell 1,"/>
  <result pre="against the MSRV envelope protein, pharmacodynamic responses in patients with" exact="multiple sclerosis" post="F Curtin 1 1GeNeuro, Plan les Ouates, Switzerland Background:"/>
  <result pre="and autoimmune cascade via Toll-Like receptor 4. MSRV-Env expressed in" exact="multiple sclerosis" post="(MS) plaques has an inhibitory effect on oligodendrocyte precursor"/>
  <result pre="of the Multiple Sclerosis associated Retrovirus (MSRV) Env protein in" exact="multiple sclerosis" post="(MS) patients. Methods: We report the results of Phase"/>
  <result pre="from invariant NKT (iNKT) cells, would suppress the development of" exact="autoimmune disease" post="models, including experimental autoimmune encephalomyelitis (EAE) (Miyamoto et al."/>
  <result pre="suppress the development of autoimmune disease models, including experimental autoimmune" exact="encephalomyelitis" post="(EAE) (Miyamoto et al. Nature 2001). Objectives: Here we"/>
  <result pre="gene expressions of whole blood with DNA microarray. Results: Mild" exact="leukopenia" post="occurred in two subjects, but recovered without any treatments."/>
  <result pre="to start an early phase 2 study for patients with" exact="multiple sclerosis" post="(MS). At April 2012, we have finished administration of"/>
  <result pre="The placebo-controlled portion of prior trials in patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS) was 1 year in duration. Objectives: To evaluate"/>
  <result pre="patients who had experienced a first clinical episode suggestive of" exact="multiple sclerosis" post="(MS). Teriflunomide 14 mg reduced the risk of relapse"/>
  <result pre="measures and an acceptable safety profile in patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS) in the Phase 3 DEFINE and CONFIRM studies."/>
  <result pre="a once-daily oral immunomodulator approved for the treatment of relapsing-remitting" exact="multiple sclerosis." post="In phase 2 and 3 studies, teriflunomide has shown"/>
  <result pre="to evaluate an integrated approach for optimized patient management in" exact="multiple sclerosis" post="patients treated with natalizumab H-P Hartung 1, T Ziemssen"/>
  <result pre="referral system on outcome of natalizumab (Tysabri ®) treated relapsing-remitting" exact="multiple sclerosis" post="(RRMS) patients, an open-label real-world study is being conducted"/>
  <result pre="Pharmaceuticals Corporation, East Hanover, NJ, United States Background: In relapsing-remitting" exact="multiple sclerosis" post="(RRMS), the presence of gadolinium-enhancing (Gd+) T1 lesions on"/>
  <result pre="Free Status? http://www.clevelandclinicmeded.com/online/webcasts/ms-vgr/treating-to-target-in-MS/. P103 Alemtuzumab improves MRI outcomes in relapsing-remitting" exact="multiple sclerosis" post="patients who relapsed on prior therapy: three-year follow-up of"/>
  <result pre="is approved in over 30 countries for treatment of relapsing-remitting" exact="multiple sclerosis" post="(RRMS). In the CARE-MS II trial in active RRMS"/>
  <result pre="P105 A double-blind, randomized, versus-placebo study of palmitoylethanolamide in relapsing-remitting" exact="multiple sclerosis" post="N Orefice 1, M Calabrese 2, A Carotenuto 3,"/>
  <result pre="been reported to reduce inflammatory markers in animal models of" exact="multiple sclerosis" post="(MS). Objectives: To evaluate the potential antiinflammatory effects of"/>
  <result pre="High Yield Process (HYP) demonstrated benefits in treatment of relapsing-remitting" exact="multiple sclerosis" post="(RRMS) in a large Phase 2b trial (SELECT). Objectives:"/>
  <result pre="(S1PR) modulator, is approved for the treatment of relapsing remitting" exact="multiple sclerosis" post="(RRMS) and more than 91,500 patients have been treated"/>
  <result pre="daily clinical routine. P108 Efficacy of delayed-release dimethyl fumarate in" exact="multiple sclerosis" post="patients with moderate disability: an integrated analysis of the"/>
  <result pre="measures and an acceptable safety profile in patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS) in the Phase 3 DEFINE and CONFIRM studies."/>
  <result pre="to have a direct effect on the CNS-based pathology in" exact="multiple sclerosis" post="by acting on S1P1 and/or S1P5 receptor expressing cells"/>
  <result pre="and lesion count reduction. Methods: Data from 296 relapsing remitting" exact="multiple sclerosis" post="patients from the placebo-controlled phase II study was analyzed."/>
  <result pre="fumarate (DMF) demonstrated efficacy and safety in patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS) in the 2-year, Phase 3 DEFINE and CONFIRM"/>
  <result pre="is in clinical development for the treatment of secondary progressive" exact="multiple sclerosis" post="(SPMS). MIS416 is a microparticulate formulation of bacterial ligands"/>
  <result pre="magnetic resonance imaging (MRI) and clinical outcomes in patients with" exact="multiple sclerosis" post="(MS) has been demonstrated in two large phase 3,"/>
  <result pre="function P114 Independent component analysis of cognitive performance in primary-progressive" exact="multiple sclerosis" post="M Petracca 1,2, H Bender 2, C Farrell 2,"/>
  <result pre="and cognitive impairment: comparison between relapsing remitting and secondary progressive" exact="multiple sclerosis" post="F Tona 1, E Sbardella 1,2, N Petsas 1,2,"/>
  <result pre="Strasbourg, Neurologie, Strasbourg, France Background: Affective disorders are frequent in" exact="multiple sclerosis" post="(MS), but their specificity remains controversial and the underlying"/>
  <result pre="intrinsic resting-state functional connectivity modulation induced by mental effort in" exact="multiple sclerosis" post="patients with fatigue C Zecca 1, E Pravatà 1,2,3,"/>
  <result pre="Background: Fatigue is a common and debilitating symptom related to" exact="multiple sclerosis" post="(MS). Fatigue may follow physical or mental efforts, resulting"/>
  <result pre="of thalamo-cortical projections. P118 Brief computerized cognitive testing in pediatric-onset" exact="multiple sclerosis" post="(MS) LE Charvet 1,2, MW Porter 1,2, B Harel"/>
  <result pre="first sign of neurocognitive impairment in children and teens with" exact="multiple sclerosis" post="(MS). Prompt identification of pediatric MS patients with impaired"/>
  <result pre="are a major determinant of impaired neuropsychological performance (NP) in" exact="multiple sclerosis" post="(MS). Previous data suggested that focal juxta- and leuko-cortical"/>
  <result pre="a history of major medical, neurologic or psychiatric illnesses, active" exact="substance abuse," post="current psychoactive medication usage (chronic sedatives/hypnotics and narcotic analgesics),"/>
  <result pre="Assessment for Multiple Sclerosis and the brief repeatable battery in" exact="multiple sclerosis" post="patients E Portaccio 1, B Goretti 1, C Niccolai"/>
  <result pre="and magnetic resonance imaging (MRI) has been investigated extensively in" exact="multiple sclerosis" post="(MS), MRI correlates of CI in CIS patients are"/>
  <result pre="impairment has been estimated to affect 45-65% of patients with" exact="multiple sclerosis" post="(MS), with deficits in executive function among the most"/>
  <result pre="3Azienda Ospedaliera Universitaria Integrata, Neurology Unit, Verona, Italy Background: Benign" exact="multiple sclerosis" post="(BMS) definition is generally based on a minimum disease"/>
  <result pre="domains P134 SDMT performance predicts real-world functioning in adults with" exact="multiple sclerosis" post="(MS) LE Charvet 1,2, M Kasschau 1,2, W Scherl"/>
  <result pre="an expanded version of a system developed for use in" exact="dementia" post="populations and previously validated for use in an MS"/>
  <result pre="and psychoaffective disturbances may present already in children affected by" exact="multiple sclerosis" post="(MS). The most vulnerable areas include attention, visual-perceptual abilities,"/>
  <result pre="in 25% of patients, may represent the first attack of" exact="multiple sclerosis" post="(MS). Although cognitive impairment (CI) has been well described"/>
  <result pre="variability is associated with white matter microstructure in persons with" exact="multiple sclerosis" post="MA Wojtowicz 1, EL Mazerolle 2, A Omisade 1,"/>
  <result pre="attention and information processing speed are common in persons with" exact="multiple sclerosis" post="(MS) and may contribute to impairments of other cognitive"/>
  <result pre="cerebellum in cognitive test performance in children and adolescents with" exact="multiple sclerosis" post="K Weier 1, C Till 2,3, V Fonov 1,"/>
  <result pre="Children’s Hospital of Philadelphia, Philadelphia, PA, United States Background: Pediatric-onset" exact="multiple sclerosis" post="(MS) is often accompanied by cognitive impairment. Severity of"/>
  <result pre="cognitive fatigue is a function of time on task in" exact="multiple sclerosis" post="J Sandry 1,2, H Genova 1,2, J DeLuca 1,2,3,"/>
  <result pre="task. P142 Response inhibition on a Go/No-go task in pediatric-onset" exact="multiple sclerosis" post="patients: an fMRI study M Lysenko 1, N Akbar"/>
  <result pre="to withhold a response, is typically preserved in patients with" exact="multiple sclerosis" post="(MS), despite impairment in other executive functions. The role"/>
  <result pre="and cognitive reserve as moderators of cognitive decline in pediatric-onset" exact="multiple sclerosis" post="patients C Till 1,2, B Hosseini 1, D Flora"/>
  <result pre="information across the corpus callosum is slowed in patients with" exact="multiple sclerosis" post="compared to healthy controls J Bacon 1,2, T Bacon"/>
  <result pre="is a frequent and early locus of disease activity in" exact="multiple sclerosis" post="(MS) . We predicted that, relative to controls, MS"/>
  <result pre="particularly relevant to study the early mechanisms of CI in" exact="multiple sclerosis" post="(MS). Diffusion tensor imaging (DTI) allows to study white"/>
  <result pre="is a sensitive measure of information processing speed deficits in" exact="multiple sclerosis" post="(MS) and has been demonstrated to be more palatable"/>
  <result pre="drive in the individual patient. P148 Inhibitory control in early" exact="multiple sclerosis" post="L Crivelli 1, MF Farez 1, RF Allegri 1,"/>
  <result pre="States Background: Cognitive dysfunction is a frequently occurring symptom of" exact="multiple sclerosis" post="(MS) and it has become an increasingly important focus"/>
  <result pre="future thinking and their relation to cerebral structure in early" exact="multiple sclerosis" post="patients GO Nygaard 1,2, KB Walhovd 3, AM Fjell"/>
  <result pre="Background: Self-reported episodic memory may be affected in relapsing remitting" exact="multiple sclerosis" post="(RRMS), but it is not clear whether it is"/>
  <result pre="France Background: Assessment of cognitive impairment (CI) in persons with" exact="multiple sclerosis" post="(PwMS) requires large neuropsychological (NP) batteries covering different domains:"/>
  <result pre="Incipient cognitive dysfunction revealed by dual-task posturography in patients with" exact="multiple sclerosis" post="L Prosperini 1, L De Giglio 1, L Castelli"/>
  <result pre="independently associated with postural instability and falls in patients with" exact="multiple sclerosis" post="(MS). However, whether a dual-task paradigm may even reveal"/>
  <result pre="processing speed test is associated with verbal memory abilities in" exact="multiple sclerosis" post="C Mavis 1,2, B Roberg 1, S O’Bryan 1,"/>
  <result pre="and auditory verbal memory are frequently impaired in people with" exact="multiple sclerosis" post="(MS). Whereas information processing speed can be quickly assessed,"/>
  <result pre="NS, Canada Background: Cognitive impairments are common among persons with" exact="multiple sclerosis" post="(MS) as are subjective cognitive complaints. The association between"/>
  <result pre="of information processing speed. P156 Cognitive impairment, oxidative stress and" exact="neurodegeneration" post="in multiple sclerosis AJ Hughes 1, I-Y Choi 2,"/>
  <result pre="processing speed. P156 Cognitive impairment, oxidative stress and neurodegeneration in" exact="multiple sclerosis" post="AJ Hughes 1, I-Y Choi 2, P Lee 3,"/>
  <result pre="Kansas City, KS, United States Background: Accumulating evidence points to" exact="neurodegeneration" post="as the primary force driving cognitive impairment in multiple"/>
  <result pre="to neurodegeneration as the primary force driving cognitive impairment in" exact="multiple sclerosis" post="(MS). In addition to examining traditional structural markers of"/>
  <result pre="sclerosis (MS). In addition to examining traditional structural markers of" exact="neurodegeneration" post="(e.g., atrophy), recent work in our laboratory has assessed"/>
  <result pre="and modestly correlated with GSH. Results provide further evidence for" exact="neurodegeneration" post="as the most likely process underlying cognitive impairment in"/>
  <result pre="of Wechsler Memory Scale-fourth edition (WMS-IV) in memory evaluation in" exact="multiple sclerosis" post="patients CT Spedo 1,2, MP Foss 1, DA Pereira"/>
  <result pre="To investigate the memory functioning and its processes in relapsing-remitting" exact="multiple sclerosis" post="patients (MS-RR) and to compare it with healthy controls"/>
  <result pre="in MS-RR. P158 Cognitive impairment and corpus callosum atrophy in" exact="multiple sclerosis" post="MY Pérez Martín 1, M González Platas 1, A"/>
  <result pre="Spain Background: Cognitive impairment affects 43-75% of the patients with" exact="multiple sclerosis" post="patients (MS). Several studies have shown that neuropsychological impairment"/>
  <result pre="P159 Do disease modifying treatments affect cognitive performance in early" exact="multiple sclerosis?" post="MC Graves 1, K Ribbons 2, R Lea 3,"/>
  <result pre="7University of Newcastle, Newcastle, Australia Background: Cognition is impaired in" exact="multiple sclerosis" post="(MS) even in early disease. Objectives: The aim of"/>
  <result pre="is known to be a common and debilitating consequence of" exact="multiple sclerosis" post="(MS), affecting approximately 43-60% of MS with a significant"/>
  <result pre="into adequate rehabilitation protocols. P162 Cognitive impairment in patients with" exact="neuromyelitis optica" post="spectrum disorder: a preliminary report S-H Kim 1, J-W"/>
  <result pre="studies have recently reported that about half of patients with" exact="neuromyelitis optica" post="spectrum disorder (NMOSD) have cognitive impairment. However, the patterns"/>
  <result pre="for Multiple Sclerosis during treatment of relapses in patients with" exact="multiple sclerosis" post="O Oztürk 1, B Piri Cinar 2, S Ozakbas"/>
  <result pre="Turkey Background: As would be expected a substantial number of" exact="multiple sclerosis" post="(MS) patients are compromised neuropsychologically. The Expanded Disability Status"/>
  <result pre="executive control components of working memory equally affected in pediatric-onset" exact="multiple sclerosis" post="patients? C Till 1,2, M Sadeghi 1, M Lysenko"/>
  <result pre="Working memory (WM) dysfunction is common amongst patients with pediatric-onset" exact="multiple sclerosis" post="(MS). WM consists of two key cognitive functions, storage"/>
  <result pre="Modalities Test: demographic effects on identification of impairment in Dutch" exact="multiple sclerosis" post="patients J Burggraaff 1, D Knol 2, B Uitdehaag"/>
  <result pre="volume is related to decreased information processing speed in relapse-remitting" exact="multiple sclerosis" post="patients T Uher 1, J Blahova-Dusankova 1, M Tyblova"/>
  <result pre="important predictor of relapse activity and sustained disability progression in" exact="multiple sclerosis" post="(MS) patients. However, there are only few large studies"/>
  <result pre="contribution of cortical lesions to cognitive impairment in patients with" exact="multiple sclerosis" post="O Geisseler 1, T Pflugshaupt 1,2, L Bezzola 3,"/>
  <result pre="that grey matter lesions occur frequently and early in all" exact="multiple sclerosis" post="phenotypes. However, the impact on cognitive and clinical impairment"/>
  <result pre="on cognitive tests. P171 Reaction time distributions in early-phase relapsing-remitting" exact="multiple sclerosis" post="differ from controls GT Howell 1, J-A LeFevre 1,2,"/>
  <result pre="of mean RT differences on the CTIP between patients with" exact="multiple sclerosis" post="(MS) and matched controls, potentially due to the MS"/>
  <result pre="Predictivity of executive functions deficit on episodic memory disorder in" exact="multiple sclerosis" post="R Barthelemy 1,2, B Lenne 1,3, D Leuse 1,"/>
  <result pre="risk behaviors P174 Does smoking influence MRI disease activity in" exact="multiple sclerosis?" post="SAS Kvistad 1, K-M Myhr 1, T Holmøy 2,"/>
  <result pre="an effect on the disease course. P176 Obesity interacts with" exact="infectious mononucleosis" post="in risk of multiple sclerosis L Alfredsson 1, AK"/>
  <result pre="course. P176 Obesity interacts with infectious mononucleosis in risk of" exact="multiple sclerosis" post="L Alfredsson 1, AK Hedström 1, IL Bomfim 2,"/>
  <result pre="Environmental risk factors influencing MS risk include a history of" exact="infectious mononucleosis" post="(IM) and adolescent obesity. Obesity results in a state"/>
  <result pre="Objectives: We aimed to investigate the possible interaction between adolescent" exact="obesity" post="and past IM with regard to MS risk. Methods:"/>
  <result pre="of HLA status, a substantial interaction was observed between adolescent" exact="obesity" post="and past IM with regard to MS risk. The"/>
  <result pre="MS was 14.7 (95% CI 5.9-36.6) among subjects with adolescent" exact="obesity" post="and past IM after the age of 10, compared"/>
  <result pre="between adolescent BMI and past IM. Measures taken against adolescent" exact="obesity" post="may thus be a preventive strategy against MS. P177"/>
  <result pre="inflammatory bowel disease (IBD) but presumably can induce or unmask" exact="multiple sclerosis" post="(MS) and MS-like idiopathic inflammatory-demyelinating disease of the central"/>
  <result pre="anti-TNFα exposure was estimated for IBD, Crohn’s disease (CD) and" exact="ulcerative colitis" post="(UC) groups separately (Wilcoxon rank sum and Fischer exact"/>
  <result pre="exposure was estimated for IBD, Crohn’s disease (CD) and ulcerative" exact="colitis" post="(UC) groups separately (Wilcoxon rank sum and Fischer exact"/>
  <result pre="in 2000 (0.2%). P178 Prescription drug use among patients with" exact="multiple sclerosis" post="LW Svenson 1,2,3, DP Schopflocher 1,3,4, SA Warren 5"/>
  <result pre="2.9). MS patients were less likely to receive drugs for" exact="cardiovascular disease" post="(OR = 0.8, 95% CI: 0.76, 0.84), anti-parasitic (OR"/>
  <result pre="treatment of common MS co-morbidities. P179 Comorbidities in patients with" exact="multiple sclerosis" post="compared with the general population: retrospective analysis of the"/>
  <result pre="Background: Limited data are available regarding comorbidities in patients with" exact="multiple sclerosis" post="(MS). Results from a retrospective study using the US"/>
  <result pre="more common in the MS vs non-MS cohort. ERs for" exact="breast cancer" post="were similar in both cohorts (1.1, 1.0-1.2). These ERRs"/>
  <result pre="common in the MS vs non-MS cohort. ERs for breast" exact="cancer" post="were similar in both cohorts (1.1, 1.0-1.2). These ERRs"/>
  <result pre="vs DOD database. Conclusions: ERs of comorbidities, such as ischaemic" exact="stroke" post="and opportunistic infections, were higher in patients with MS"/>
  <result pre="sleep disruption. The more common sleep disorders include insomnia, sleepness," exact="sleep apnea," post="restless legs syndrome (RLS) or narcolepsy. Frequently, these disturbances"/>
  <result pre="The more common sleep disorders include insomnia, sleepness, sleep apnea," exact="restless legs syndrome" post="(RLS) or narcolepsy. Frequently, these disturbances have a major"/>
  <result pre="patients seen in the DD consultation and the relationship of" exact="sleep disorder" post="and QoL and fatigue. Methods: 240 patients were included;"/>
  <result pre="included; mean age 43±11 years, 187 women. 163 patients with" exact="multiple sclerosis" post="(MS): 144 relapsing-remitting (RR), 14 secondary progressive (SP) and"/>
  <result pre="Moderate/severe insomnia 12.5%, OSA 5.8%, RLS 9.6% (confirmed three cases)," exact="narcolepsy" post="0, fatigue (&amp;gt;4) 24.6%. Physical QoL 66.6±19.6, Mental QoL"/>
  <result pre="seems to be growing evidence of an association between adolescent" exact="obesity" post="and increased risk of multiple sclerosis (MS), it has"/>
  <result pre="of an association between adolescent obesity and increased risk of" exact="multiple sclerosis" post="(MS), it has yet to be determined if weight"/>
  <result pre="potentially influence lifestyle and dietary habits. P182 Alcohol-use disorders and" exact="multiple sclerosis" post="risk: a national record-linkage study J Pakpoor 1, R"/>
  <result pre="of people with a record for alcohol use (10156 people)," exact="alcohol abuse" post="(255827 people) and alcohol dependence (281305 people) were constructed"/>
  <result pre="for alcohol use (10156 people), alcohol abuse (255827 people) and" exact="alcohol dependence" post="(281305 people) were constructed by identifying the first recorded"/>
  <result pre="a significantly increased risk of MS following alcohol use (p=0.003)," exact="alcohol abuse" post="(p&amp;lt; 0.0001) and alcohol dependence (p=0.001). Considering the possibility"/>
  <result pre="MS following alcohol use (p=0.003), alcohol abuse (p&amp;lt; 0.0001) and" exact="alcohol dependence" post="(p=0.001). Considering the possibility of reverse causality we found"/>
  <result pre="risk of MS within one year of first admission for" exact="alcohol abuse" post="only (p&amp;lt; 0.0001), but not for alcohol use or"/>
  <result pre="follow-up studies are required to ascertain the relationship. P183 The" exact="metabolic syndrome" post="in disabled multiple sclerosis patients: prevalence and characteristics M"/>
  <result pre="to ascertain the relationship. P183 The metabolic syndrome in disabled" exact="multiple sclerosis" post="patients: prevalence and characteristics M Livne 1,2, O Pinhas-Hamiel"/>
  <result pre="the association of metabolic commodities and disability in patients with" exact="multiple sclerosis" post="(MS). Objectives: To examine the prevalence of the metabolic"/>
  <result pre="multiple sclerosis (MS). Objectives: To examine the prevalence of the" exact="metabolic syndrome" post="(MetS) and characterize its components in MS patients with"/>
  <result pre="of any three of the following five components 1) central" exact="obesity" post="as measured by WC (males &amp;gt;102 cm, females &amp;gt;88"/>
  <result pre="for males and &amp;lt; 50 mg/dl for females, or treated" exact="dyslipidemia" post="4) blood pressure &amp;gt;135/85 or treated hypertension, and 5)"/>
  <result pre="MetS was 36.9% with no gender difference. 55.9% had central" exact="obesity" post="by WC, 28 % had treated hypertension, and 45.8%"/>
  <result pre="and 45.8% had elevated blood pressure, 11% had type 2" exact="diabetes mellitus" post="and 36.4% had hyperglycemia, 31.4% had treated dyslipidemia and"/>
  <result pre="2 diabetes mellitus and 36.4% had hyperglycemia, 31.4% had treated" exact="dyslipidemia" post="and 28.8% had elevated TG level, 31.4 had low"/>
  <result pre="related effect. P184 Burden of comorbidities in patients with incident" exact="multiple sclerosis" post="prior to and following diagnosis: a nationwide population study"/>
  <result pre="Taoyuan, Taiwan, Republic of China Background: Comorbidities in individuals with" exact="multiple sclerosis" post="(MS) may delay diagnosis and the accumulation of comorbidities"/>
  <result pre="P185 Smoking, systemic inflammation and T-cell reactivity in patients with" exact="multiple sclerosis" post="and healthy controls C Ammitzboell 1, LS Börnsen 1,"/>
  <result pre="neuroinflammation, axonal damage and disease progression in patients with progressive" exact="multiple sclerosis" post="(MS). Smoking is one of the environmental factors associated"/>
  <result pre="from HCs. P186 Tobacco influence in the clinical progression of" exact="multiple sclerosis" post="S Batista 1, Z Argyropoulou 2, I Correia 1,"/>
  <result pre="effect in the disease evolution. P187 Prevalence and predictors of" exact="substance abuse" post="in multiple sclerosis N Brennecke 1, AL Boster 2,3,"/>
  <result pre="disease evolution. P187 Prevalence and predictors of substance abuse in" exact="multiple sclerosis" post="N Brennecke 1, AL Boster 2,3, AM Wehr 4,"/>
  <result pre="Department of Biostatistics, Columbus, OH, United States Background: Patients with" exact="multiple sclerosis" post="(MS) have been shown to be more likely to"/>
  <result pre="population, creating interest in the prevelance and risk factors for" exact="substance abuse" post="among this patient population. Objectives: To assess the prevalence"/>
  <result pre="among this patient population. Objectives: To assess the prevalence of" exact="substance abuse" post="among MS patients in a large, academic MS clinic"/>
  <result pre="large, academic MS clinic and to identify predictors associated with" exact="substance abuse." post="Methods: MS patients presenting for routine clinic visits at"/>
  <result pre="model using backward selection was performed to identify predictors of" exact="substance abuse." post="Results: A total of 255 MS patients were included"/>
  <result pre="total of 29 patients (12%) were identified to have current" exact="substance abuse," post="208 (88%) did not currently abuse substances and 18"/>
  <result pre="status was found to be a significant predictor of current" exact="substance abuse." post="For unemployed patients with MS, the odds of current"/>
  <result pre="abuse. For unemployed patients with MS, the odds of current" exact="substance abuse" post="was 4.67 times that of an employed patient with"/>
  <result pre="MS patient population. Unemployment significantly increased the risk of current" exact="substance abuse." post="Race, age, sex, MS disease course, disability and marital"/>
  <result pre="course, disability and marital status were not significant predictors of" exact="substance abuse." post="Larger studies are needed to confirm the results obtained"/>
  <result pre="needed to confirm the results obtained from this study. Since" exact="substance abuse" post="may adversely affect MS patient health and ability to"/>
  <result pre="to remain adherent to MS disease modifying therapy, screening for" exact="substance abuse" post="should be considered by MS specialists, especially among patients"/>
  <result pre="Hospital of Philadelphia, Philadelphia, PA, United States Background: Overweight and" exact="obesity" post="in childhood and early adolescence has been associated with"/>
  <result pre="United States Background: Neurological reserve may slow disease progression in" exact="multiple sclerosis" post="(MS), and is associated with not engaging in destructive"/>
  <result pre="interventions are discussed. P190 Concomitant diseases and MRI outcomes in" exact="multiple sclerosis" post="R Zivadinov 1,2, B Raj 1, M Ramanathan 2,"/>
  <result pre="United States Background: While concomitant diseases occur in association with" exact="multiple sclerosis" post="(MS), no studies utilized sensitive magnetic resonance imaging (MRI)"/>
  <result pre="on each disease and category. The Th1 mediated disease included:" exact="systemic lupus erythematosus," post="rheumatoid arthritis, Crohn’s disease, diabetes mellitus type 1, manic"/>
  <result pre="each disease and category. The Th1 mediated disease included: systemic" exact="lupus erythematosus," post="rheumatoid arthritis, Crohn’s disease, diabetes mellitus type 1, manic"/>
  <result pre="and category. The Th1 mediated disease included: systemic lupus erythematosus," exact="rheumatoid arthritis," post="Crohn’s disease, diabetes mellitus type 1, manic depressive illness,"/>
  <result pre="mediated disease included: systemic lupus erythematosus, rheumatoid arthritis, Crohn’s disease," exact="diabetes mellitus" post="type 1, manic depressive illness, psoriasis, allergies, thyroiditis and"/>
  <result pre="disease, diabetes mellitus type 1, manic depressive illness, psoriasis, allergies," exact="thyroiditis" post="and myasthenia gravis. The Th2 mediated diseases included asthma"/>
  <result pre="mellitus type 1, manic depressive illness, psoriasis, allergies, thyroiditis and" exact="myasthenia gravis." post="The Th2 mediated diseases included asthma and ulcerative colitis,"/>
  <result pre="allergies, thyroiditis and myasthenia gravis. The Th2 mediated diseases included" exact="asthma" post="and ulcerative colitis, while non-Th-mediated disease included cancer, diabetes"/>
  <result pre="and myasthenia gravis. The Th2 mediated diseases included asthma and" exact="ulcerative colitis," post="while non-Th-mediated disease included cancer, diabetes mellitus type 2,"/>
  <result pre="included asthma and ulcerative colitis, while non-Th-mediated disease included cancer," exact="diabetes mellitus" post="type 2, epilepsy, irritable bowel syndrome migraine and chronic"/>
  <result pre="while non-Th-mediated disease included cancer, diabetes mellitus type 2, epilepsy," exact="irritable bowel syndrome" post="migraine and chronic obstructive pulmonary disease. The MRI outcomes"/>
  <result pre="included cancer, diabetes mellitus type 2, epilepsy, irritable bowel syndrome" exact="migraine" post="and chronic obstructive pulmonary disease. The MRI outcomes included"/>
  <result pre="diabetes mellitus type 2, epilepsy, irritable bowel syndrome migraine and" exact="chronic obstructive pulmonary disease." post="The MRI outcomes included lesion, atrophy magnetization transfer ratio"/>
  <result pre="Th1 and Th2 effects. P191 Multiple sclerosis in patients with" exact="common variable immunodeficiency" post="disease: co-incidence or consequence? K Pandey 1,2, I Kister"/>
  <result pre="despite deficiency in functional antibodies, autoimmune diseases such as cytopenias," exact="autoimmune hepatitis" post="or inflmmatory bowel disease, affect about 20% of CVID"/>
  <result pre="deficiency in functional antibodies, autoimmune diseases such as cytopenias, autoimmune" exact="hepatitis" post="or inflmmatory bowel disease, affect about 20% of CVID"/>
  <result pre="first clinical manifestation of immune deficiency . To our knowledge," exact="multiple sclerosis" post="(MS) has not been reported as an autoimmune condition"/>
  <result pre="Ramat Gan, Israel, 4Medistat, Tel-Aviv, Israel Background: We hypothesized that" exact="multiple sclerosis" post="(MS) patients with significant disability will be heavier than"/>
  <result pre="Overweight was defined as 25kg/m 2&amp;lt; BMI&amp;lt; 30kg/m 2 and" exact="obesity" post="was defined as BMI≥30kg/m 2. Comparison was performed with"/>
  <result pre="comorbid psychiatric disorders in worsening the quality of life in" exact="multiple sclerosis" post="patients L Lorefice 1, G Trincas 2, MF Moro"/>
  <result pre="determinant in reducing QoL, in particular in MS patients without" exact="mood disorder" post="(p&amp;lt; 0.0001). No association was found for other clinical"/>
  <result pre="the management of MS. P194 Subclinical coronary artery disease in" exact="multiple sclerosis" post="patients E Andreadou 1, S Gerakoulis 1, V Haina"/>
  <result pre="Hospital, Athens, Greece Background: The incidence and prevalence of ischemic" exact="heart disease" post="in the MS population has been reported to be"/>
  <result pre="Genetic risk factors are associated with cerebrospinal fluid measures in" exact="multiple sclerosis" post="A Goris 1, I Pauwels 1, MW Gustavsen 2,3,"/>
  <result pre="Department of Molecular Biology, Oslo, Norway Background: Immunological hallmarks of" exact="multiple sclerosis" post="(MS) are production of antibodies expressed as oligoclonal bands"/>
  <result pre="IGHC region as major determinants. P196 CSF isoelectric focusing differentiates" exact="multiple sclerosis" post="from other CNS autoimmune disorders E Bernitsas 1, F"/>
  <result pre="studies have examined the utility of CSF IEF in distinguishing" exact="multiple sclerosis" post="from other CAID. Objectives: To examine the presence of"/>
  <result pre="other CAID were included in the study. Other CAID included" exact="vasculitis" post="(n=6), Sjogren’s (n=7), sarcoidosis (n=30), lupus (n=6), and anti-phospholipid"/>
  <result pre="in the study. Other CAID included vasculitis (n=6), Sjogren’s (n=7)," exact="sarcoidosis" post="(n=30), lupus (n=6), and anti-phospholipid antibody syndrome (n=4), all"/>
  <result pre="patients presenting with a clinically isolated syndrome (CIS) suggestive of" exact="multiple sclerosis" post="(MS) do not fulfil the MRI criteria for dissemination"/>
  <result pre="2010 criteria. P198 Comprehensive Immunophenotyping of CSF cells in relapsing-remitting" exact="multiple sclerosis" post="patients with daclizumb therapy Y-C Lin 1, P Winokur"/>
  <result pre="chain of IL-2 receptor (IL-2Ra; CD25) stabilizes clinical symptoms of" exact="multiple sclerosis" post="(MS), the debilitating neuro-inflammatory disorder. By using 12 color"/>
  <result pre="who tolerate this treatment long-term. P199 Intrathecal B-cell response in" exact="multiple sclerosis" post="brain recognizes auto-antigens DL Walker 1, CE Estrem 1,"/>
  <result pre="response may act as antigen-presenting cells that mediate demyelination or" exact="neurodegeneration" post="in MS. P200 Increased intrathecal inflammation in progressive multiple"/>
  <result pre="or neurodegeneration in MS. P200 Increased intrathecal inflammation in progressive" exact="multiple sclerosis" post="M Komori 1, A Blake 1, Y-C Lin 1,"/>
  <result pre="Background: Lack of therapeutic efficacy of immunomodulatory therapies in progressive" exact="multiple sclerosis" post="(MS) has been interpreted as evidence that neurodegeneration rather"/>
  <result pre="progressive multiple sclerosis (MS) has been interpreted as evidence that" exact="neurodegeneration" post="rather than immunopathology drives central nervous system (CNS) tissue"/>
  <result pre="prognostic marker in MS. P202 Intrathecal IgG from patients with" exact="multiple sclerosis" post="target patient-specific phage peptides T Pointon 1, S Manton"/>
  <result pre="at onset 31.2±7.7 years. The most frequent presenting syndrome was" exact="optic neuritis" post="(31.9%) followed by transverse myelitis (28.6%). LS-OCMB were present"/>
  <result pre="frequent presenting syndrome was optic neuritis (31.9%) followed by transverse" exact="myelitis" post="(28.6%). LS-OCMB were present in 17.6% patients, and all"/>
  <result pre="Subclinical intrathecal inflammation is risk for disease reactivation in early" exact="multiple sclerosis" post="S Rossi 1,2, V Studer 1,2, C Motta 1,2,"/>
  <result pre="Italy Background: Pathogenic events leading to brain structural damage in" exact="multiple sclerosis" post="(MS) start early, independently of clinical signs. An earlier"/>
  <result pre="presence of oligoclonal bands (OCBs) in cerebrospinal fluid (CSF) of" exact="multiple sclerosis" post="(MS) is now well established to support the clinical"/>
  <result pre="them were diagnosed clinically isolated syndrome (CIS), 49% relapsing remitting" exact="multiple sclerosis" post="(RRMS) according to Poser criteria, 11.8% secondary progressive MS"/>
  <result pre="was diagnosed other inflammatory neurological diseases (OIND) (9.8%) (1pt with" exact="chronic inflammatory demyelinating polyneuropathy," post="1pt with neuromyelitis optica, 1pt with paraneoplastic syndrome, 2pts"/>
  <result pre="(OIND) (9.8%) (1pt with chronic inflammatory demyelinating polyneuropathy, 1pt with" exact="neuromyelitis optica," post="1pt with paraneoplastic syndrome, 2pts with acute disseminated encephalomyelitis)."/>
  <result pre="the pivotal studies were not intended to aggressive forms of" exact="multiple sclerosis" post="(MS). Objectives: To investigate whether the presence of LS-OCMB"/>
  <result pre="times to failure to first-line therapies. P207 miR-142-3p expression in" exact="multiple sclerosis" post="cerebrospinal fluid is related to better cognitive performance L"/>
  <result pre="Neuritis (CRION/RION). Sometimes the initial diagnosis can be difficult because" exact="optic neuritis" post="and/or myelitis are clinical syndromes shared to all these"/>
  <result pre="the initial diagnosis can be difficult because optic neuritis and/or" exact="myelitis" post="are clinical syndromes shared to all these medical conditions."/>
  <result pre="and more time than traditional LP. P210 Oligoclonal bands predict" exact="multiple sclerosis" post="in children with isolated optic neuritis: a retrospective multicenter"/>
  <result pre="13University of Würzburg, Department of Neuropediatrics, Würzburg, Germany Background: Isolated" exact="optic neuritis" post="(ON) in childhood may remain a singular event or"/>
  <result pre="remain a singular event or indicate the clinical beginning of" exact="multiple sclerosis" post="(MS). Higher age and pathological cranial MRI at presentation"/>
  <result pre="risk factors, including cerebrospinal fluid findings, in children with isolated" exact="optic neuritis" post="as a first demyelinating event. Methods: Only children with"/>
  <result pre="nervous system but also in the CSF of patients with" exact="multiple sclerosis" post="(MS). In MS intrathecal IgM synthesis seems to correlated"/>
  <result pre="Lipid-specific oligoclonal IgM bands and cognition in early stages of" exact="multiple sclerosis" post="J Gich 1,2, R Menéndez 2, E Quintana 2,"/>
  <result pre="of sialylated IgG antibody in the CSF of patients with" exact="multiple sclerosis" post="T Curley 1, T Pointon 1, H Collins 1,"/>
  <result pre="Background: A characteristic feature of the CNS inflammatory response in" exact="multiple sclerosis" post="(MS) is the intrathecal synthesis of IgG and the"/>
  <result pre="sialylation in the CSF and paired serum of patients with" exact="multiple sclerosis." post="Methods: Purified IgG antibody in CSF and paired serum"/>
  <result pre="disease pathogenesis. P215 Cerebrospinal fluid markers of the course of" exact="multiple sclerosis" post="I Smagina 1, S Elchaninova 1 1Altai State Medical"/>
  <result pre="for a phenome-wide examination of the comorbidity burden associated with" exact="multiple sclerosis" post="disease outcome M Goodman 1, B Healy 2, T"/>
  <result pre="Background: Comorbid conditions can impact disease outcome and course in" exact="multiple sclerosis" post="(MS). Objectives: To perform a phenome-wide association study (PheWAS)"/>
  <result pre="OR=3.7, p=2.3e-7), venous embolism and thrombosis (n=61, OR=4.5, p=2.6e-6), and" exact="respiratory failure" post="(n=31, OR=10.5, p=9.0e-6). Finally, we found intriguing associations with"/>
  <result pre="OR=2.2, p=0.0028), as well as inverse associations with benign skin" exact="neoplasm" post="(n=248, OR=0.52, p=0.00018) and breast lump or mass (n=142,"/>
  <result pre="severe MS disability. P218 Establishment of a global registry for" exact="multiple sclerosis" post="patients on extended dose natalizumab schedules J Herbert 1,"/>
  <result pre="sclerosis (MS). However, its use is limited by susceptibility to" exact="progressive multifocal leukoencephalopathy" post="(PML) in patients with serological evidence of exposure to"/>
  <result pre="is a Web-based, global observational registry for an ‘orphan’ disorder:" exact="neuromyelitis optica" post="I Kister 1, T Bacon 1, R Alroughani 2,"/>
  <result pre="orphan diseases. P220 Argentinean registry of patients with relapsing remitting" exact="multiple sclerosis" post="treated with fingolimod (REAL): design and results of interim"/>
  <result pre="(Gilenya) is approved in Argentina for the treatment of relapsing" exact="multiple sclerosis" post="(MS) since April 2011. Despite the fact that many"/>
  <result pre="treatment was needed. One serious adverse event was reported (severe" exact="pneumonia" post="followed by death not related to fingolimod according to"/>
  <result pre="Background: Natalizumab (NTZ) is a disease modulatory treatment for relapsing-remitting" exact="multiple sclerosis" post="(RRMS) with high efficacy. However, post-marketing surveillance is important"/>
  <result pre="but included 7 non-fatal cases and 1 fatal case of" exact="progressive multifocal leukoencephalopathy" post="(PML, 0.3%), with the latest case reported 2012-10-31. The"/>
  <result pre="is an important concern. Diagnosis and differential diagnosis P222 Transverse" exact="myelitis" post="in neuro-Behcet’s disease HS Lee 1, HY Shin 1,"/>
  <result pre="University of Korea, Neurology, Seoul, Korea, Republic of Background: Transverse" exact="myelitis" post="(TM) can appear as the first manifestation in conditions"/>
  <result pre="can appear as the first manifestation in conditions such as" exact="multiple sclerosis" post="(MS) and neuromyelitis optica (NMO). However a number of"/>
  <result pre="first manifestation in conditions such as multiple sclerosis (MS) and" exact="neuromyelitis optica" post="(NMO). However a number of disorders including Behcet’s disease"/>
  <result pre="was longer than three vertebral bodies, i.e. longitudinal extensive transverse" exact="myelitis" post="(LETM). Conclusions: TM can be developed in patients with"/>
  <result pre="in patients with LETM. P223 Methionyl-tRNA formyltransferase (MTFMT) deficiency mimicking" exact="neuromyelitis optica" post="JA Pena 1,2, F Scaglia 3, TE Lotze 1,2"/>
  <result pre="TX, United States Background: Neuromyelitis optica (NMO) is typified by" exact="optic neuritis" post="and transverse myelitis, often with longitudinally extensive cord lesions."/>
  <result pre="extensive cord lesions. Brain MRI findings are otherwise atypical for" exact="multiple sclerosis." post="Rarely, mitochondrial diseases can present with features of an"/>
  <result pre="of an acquired demyelinating syndrome, such as NMO, to include" exact="optic neuropathy" post="and longitudinally extensive transverse myelitis. Objectives: We describe an"/>
  <result pre="an acquired demyelinating syndrome, such as NMO, to include optic" exact="neuropathy" post="and longitudinally extensive transverse myelitis. Objectives: We describe an"/>
  <result pre="to combined oxidative phosphorylation deficiency. Methods: Case of MTFMT mimicking" exact="neuromyelitis optica." post="Results: A 19 year old male presented with relapsing"/>
  <result pre="with relapsing longitudinally extensive transverse myelitis, brainstem demyelination, and progressive" exact="optic neuropathy." post="NMO was initially considered due to gadolinium enhancement of"/>
  <result pre="features suggestive of NMO to include a relapsing clinical course," exact="optic neuropathy," post="myelopathy associated with long cord lesions, and atypical brain"/>
  <result pre="syndrome detected by spectral domain optical coherence tomography differentiates from" exact="multiple sclerosis" post="M Ringelstein 1, P Albrecht 1, I Kleffner 2,"/>
  <result pre="of encephalopathy, sensorineural hearing deficits, and visual disturbances due to" exact="branch retinal artery occlusion" post="(BRAO) detectable by fluorescein angiography (FA). Differentiation from Multiple"/>
  <result pre="from MS. P225 Brain lesion location at onset helps differentiate" exact="neuromyelitis optica" post="and multiple sclerosis NH Kim 1, DE Kim 1,"/>
  <result pre="Brain lesion location at onset helps differentiate neuromyelitis optica and" exact="multiple sclerosis" post="NH Kim 1, DE Kim 1, SH Woo 1,"/>
  <result pre="by antibodies to aquaporin-4 water channel. Making diagnosis of antibody-negative" exact="neuromyelitis optica" post="spectrum disorder (NMOSD) is difficult because the more prevalent"/>
  <result pre="optica spectrum disorder (NMOSD) is difficult because the more prevalent" exact="multiple sclerosis" post="(MS) can present similarly. It is important to distinguish"/>
  <result pre="identify those at risk of conversion to MS. P227 Aggressive" exact="multiple sclerosis" post="S Menon 1,2,3, SA Morrow 1,2,3, M Kremenchutzky 1,2,3"/>
  <result pre="are difficult to predict at onset. Objectives: To study aggressive" exact="multiple sclerosis" post="(AMS) in a natural history MS cohort. Methods: Population"/>
  <result pre="Background: Baló’s concentric sclerosis (Baló) is a rare variant of" exact="multiple sclerosis" post="(MS) characterized by its particular multi-layered or onion-shaped lesions,"/>
  <result pre="plaques and in additional typical MS lesions. P229 Aquaporin-4 antibody-seropositive" exact="myelitis" post="initially biopsied due to suspected spinal cord tumors: diagnostic"/>
  <result pre="P230 Artificial intelligence techniques in the diagnosis of clinically definite" exact="multiple sclerosis" post="G Dalla Costa 1, L Moiola 1, L Leocani"/>
  <result pre="early identification of patients at risk of developing clinically definite" exact="multiple sclerosis" post="(CDMS) represents the main purpose of diagnostic criteria and"/>
  <result pre="clinical and paraclinical data. P231 MRI study of Leber’s hereditary" exact="optic neuropathy" post="and MS suggests common lesion pathology and an 83%"/>
  <result pre="and paraclinical data. P231 MRI study of Leber’s hereditary optic" exact="neuropathy" post="and MS suggests common lesion pathology and an 83%"/>
  <result pre="is the observation that the rare mitochondrial disease Leber’s hereditary" exact="optic neuropathy" post="(LHON) and an MS-like illness (LHON-MS) coexist more frequently"/>
  <result pre="the observation that the rare mitochondrial disease Leber’s hereditary optic" exact="neuropathy" post="(LHON) and an MS-like illness (LHON-MS) coexist more frequently"/>
  <result pre="et al., J Neurol, 2000. 247(7): p. 535-43. P232 Diagnosing" exact="multiple sclerosis" post="with a gait measuring system, an analysis of the"/>
  <result pre="other diagnoses were already possible, the most frequent diagnoses were" exact="migraine" post="(in 15 cases), vascular encephalopathy including PTO (in 13"/>
  <result pre="the most frequent diagnoses were migraine (in 15 cases), vascular" exact="encephalopathy" post="including PTO (in 13 cases), recurrent optic neuritis (in"/>
  <result pre="15 cases), vascular encephalopathy including PTO (in 13 cases), recurrent" exact="optic neuritis" post="(in 2 cases), systemic erythematous lupus (in 2 cases),"/>
  <result pre="cases), dizziness (in 2 cases), neuroBechet’s disease (in 2 cases)," exact="neuromyelitis optica" post="(in 2 cases). Conclusions: Our preliminary analysis confirm that"/>
  <result pre="patients presenting with symptoms suggestive of MS. Migraine and vascular" exact="encephalopathy" post="are by far the most frequent alternative diagnosis, while,"/>
  <result pre="with MS. P234 The thalamus and basal ganglia lesions in" exact="multiple sclerosis" post="and primary angiitis of the central nervous system in"/>
  <result pre="be helpful in making a differential diagnosis. P235 Patients with" exact="multiple sclerosis" post="criteria subsequently displayed Behçet disease signs L Ait Aissa"/>
  <result pre="P237 Magnetic resonance spectroscopy in cases of clinical conflict between" exact="multiple sclerosis," post="vasculitis and multiple lacunar infarcts of the brain SS"/>
  <result pre="resonance spectroscopy in cases of clinical conflict between multiple sclerosis," exact="vasculitis" post="and multiple lacunar infarcts of the brain SS Salama"/>
  <result pre="investigation of the normal-appearing white matter (NAWM) in patients with" exact="multiple sclerosis" post="(MS). Metabolic changes in NAWM are of special interest"/>
  <result pre="isolated syndromes (CIS) suggesting a conflicting clinical diagnosis of MS," exact="vasculitis" post="or multiple lacunar infarcts Objectives: The purpose of this"/>
  <result pre="use of high-field 1H-MR spectroscopy to help differentiate between MS," exact="vasculitis" post="and multiple lacunar infarcts. Methods: With use of a"/>
  <result pre="( posing a conflict in their diagnosis between MS and" exact="vasculitis" post="or MS and multiple lacunar infarcts) divided into three"/>
  <result pre="the suspected clinical diagnosis, suspected MS group sMS(n =16), suspected" exact="vasculitis" post="group sVasc (n=10) and suspected lacunar infarcts group sMLI"/>
  <result pre="± 0.17, P &amp;lt; 0.001) but not in the suspected" exact="vasculitis" post="and suspected multiple lacunar infarcts groups. Mean mIns /Cr"/>
  <result pre="CIS suggestive of MS but not in patients with suspected" exact="vasculitis" post="or multiple lacunar infarcts. P238 HTLV-1-associated myelopathy/tropical spastic paraparesis:"/>
  <result pre="HTLV-1-associated myelopathy/tropical spastic paraparesis: a differential diagnosis in primary progressive" exact="multiple sclerosis" post="FJ Carod Artal 1, H Mourao Mesquita 2 1Raigmore"/>
  <result pre="and thoracic spine cord (21.4%). Conclusions: TSP/HAM is a progressive" exact="neurological disorder" post="that may mimic clinically and radiologically multiple sclerosis in"/>
  <result pre="a progressive neurological disorder that may mimic clinically and radiologically" exact="multiple sclerosis" post="in endemic areas. Some patients may initially present with"/>
  <result pre="may be helpful to differentiate HAM/TSP patients from primary progressive" exact="multiple sclerosis." post="P239 Microscopic polyangiitis presenting with long extended tranverse myelitis"/>
  <result pre="multiple sclerosis. P239 Microscopic polyangiitis presenting with long extended tranverse" exact="myelitis" post="(LETMS) HÖ Köse 1, V Akdemir 2, Y Celik"/>
  <result pre="cytoplasmic antibody (MPO-ANCA). MPA often presented with rapidly progressive necrotizing" exact="glomerulonephritis" post="or alveolar hemorrhage. Neurological findings are observed in 20"/>
  <result pre="observed in 20 -50% of cases consisting of cranial and" exact="peripheral neuropathy," post="and central nervous system involvement including chronic hypertrophic pachymeningitis,"/>
  <result pre="gland involvement, intracerebral hemorrhage, multiple ischemic infarcts, subarachnoid hemorrhage and" exact="vasculitis" post="during the disease and rarely as initial symptom. Objectives:"/>
  <result pre="Microscopic polyangiitis (MPA) as initial manifestation of longitudinally extensive transverse" exact="myelitis" post="(LETM). Methods: A case report demonstrating unique LETM presentation"/>
  <result pre="chronic spastic paraparesis a clinical picture of longitudinally extensive transverse" exact="myelitis" post="(LETM). MPA should be considered as a differential diagnosis"/>
  <result pre="abscesses. Clinical and radiologic features are different than in typical" exact="multiple sclerosis" post="(MS), leading to difficulty in diagnosis and treatment. Objectives:"/>
  <result pre="P242 Glial and neuronal markers in CSF predict progression in" exact="multiple sclerosis" post="MA Mañé Martinez 1,2, B Olsson 3, L Bau"/>
  <result pre="gene and protein expression levels and microRNA (miRNA) profiles in" exact="multiple sclerosis" post="(MS) patients as biomarkers for disease status and response"/>
  <result pre="prognostic markers. P244 Interferon inducible transcriptional profile in secondary progressive" exact="multiple sclerosis" post="patients M Gurevich 1, G Miron 1, E Hanael"/>
  <result pre="the recommended immunomodulatory treatment for the treatment of secondary progressive" exact="multiple sclerosis" post="(SPMS) patients. Interferon inducible transcriptional signatures have been well"/>
  <result pre="P246 Gray matter related proteins in cerebrospinal fluid differentiate between" exact="multiple sclerosis" post="and other acquired demyelinating syndromes in childhood V Singh"/>
  <result pre="1Erasmus MC, Rotterdam, Netherlands Background: A few percent of all" exact="multiple sclerosis" post="(MS) patients experience a first attack in childhood. In"/>
  <result pre="monophasic ADS. P247 Global metabolomics identifies a metabolic profile of" exact="multiple sclerosis" post="P Bhargava 1, B Poore 2, C Nguyen 2,"/>
  <result pre="P248 CSF biomarkers of inflammation and neuronal damage in acute" exact="optic neuritis" post="predict later development of MS and long-term disability S"/>
  <result pre="(CSF) levels of inflammatory biomarkers have been suggested to predict" exact="multiple sclerosis" post="(MS) development after clinically isolated syndromes, but there is"/>
  <result pre="MS (CDMS) and long-term disability. Methods: 86 patients with acute" exact="optic neuritis" post="(ON) as a first demyelinating event seen in our"/>
  <result pre="were examined by the corresponding author incl. an EDSS and" exact="multiple sclerosis" post="functional composit (MSFC) evaluation. 18.6 % were interviewed by"/>
  <result pre="regression was used for time to CDMS, multivariate regression for" exact="multiple sclerosis" post="severity score (MSSS) and Spearman correlation and linear regression"/>
  <result pre="proteome profile of the urine is different in patients with" exact="neuromyelitis optica" post="compared to multiple sclerosis and healthy subjects HH Nielsen"/>
  <result pre="urine is different in patients with neuromyelitis optica compared to" exact="multiple sclerosis" post="and healthy subjects HH Nielsen 1, LP Kristensen 2,"/>
  <result pre="The demyelinating diseases comprise a broad spectrum of diseases like" exact="multiple sclerosis" post="(MS) neuromyelitis optica (NMO) and the NMO spectrum disorders"/>
  <result pre="comprise a broad spectrum of diseases like multiple sclerosis (MS)" exact="neuromyelitis optica" post="(NMO) and the NMO spectrum disorders (NMO-SD). Despite clear"/>
  <result pre="to a panel of biomarkers in newly diagnosed patients with" exact="multiple sclerosis" post="M Stilund 1,2, MC Gjelstrup 2, T Petersen 1,"/>
  <result pre="for the clinic and provides a useful tool for diagnosing" exact="multiple sclerosis" post="patterns. Studies of the recombinant antibodies produced from these"/>
  <result pre="being observed. P253 Peripheral blood cells from patients with benign" exact="multiple sclerosis" post="are characterized by a TNF gene expression signature NM"/>
  <result pre="P254 Cerebrospinal fluid proteome analysis reveals differentially abundant proteins in" exact="multiple sclerosis" post="J Füvesi 1, R Danielsson 2, K Bencsik 1,"/>
  <result pre="marker for ongoing axonal damage, for example in patients with" exact="multiple sclerosis." post="In order to interpret values of NFL in a"/>
  <result pre="of NFL in the healthy is required. Another biomarker for" exact="neurodegeneration" post="is the investigation of brain atrophy using magnetic resonance"/>
  <result pre="are associated with neurodegeneration, for example in the case of" exact="multiple sclerosis," post="where both are associated with increased disease activity. A"/>
  <result pre="age related neurodegeneration. P256 UP-regulation of Nod-like receptor signaling in" exact="multiple sclerosis" post="F La Rosa 1, F Piancone 1, I Marventano"/>
  <result pre="Basel, Department of Biomedicine, Basel, Switzerland Background: The patho-physiology of" exact="multiple sclerosis" post="disease onset and progression remains undetermined. Understanding this is"/>
  <result pre="proteomics studies for the detection of pathologically relevant proteins for" exact="multiple sclerosis" post="(MS). Because the course of the disease after clinically"/>
  <result pre="of biomarkers for diagnosis and therapeutic monitoring of patients with" exact="multiple sclerosis" post="(MS) has proven difficult due to the varied clinical"/>
  <result pre="in human cerebrospinal fluid (CSF) associated with disease progression in" exact="multiple sclerosis" post="(MS) and allow stratification of the two progressive disease"/>
  <result pre="from controls with no disease (n=15), patients with primary progressive" exact="multiple sclerosis" post="(PPMS; n=15), and patients with secondary progressive multiple sclerosis"/>
  <result pre="progressive multiple sclerosis (PPMS; n=15), and patients with secondary progressive" exact="multiple sclerosis" post="(SPMS; n=15) were analyzed on the GC/MS and LC/MS/MS"/>
  <result pre="as potential predictors of clinically isolated syndrome (CIS) converted to" exact="multiple sclerosis" post="(MS). Among the multitude of biomarkers which have been"/>
  <result pre="P261 Urine levels of 8-Isoprostane in relapsing-remitting and secondary progressive" exact="multiple sclerosis" post="P Kivisäkk 1, Y Hyvert 2, K Melo 1,"/>
  <result pre="8-Isoprostane are increased in cerebrospinal fluid (CSF) from patients with" exact="multiple sclerosis" post="(MS), with maximum levels in patients with secondary progressive"/>
  <result pre="urine levels as a marker of oxidative stress associated with" exact="neurodegeneration" post="during the progressive phase of MS. P262 Potential biomarkers"/>
  <result pre="for potential to lead to remyelination and functional recovery in" exact="multiple sclerosis" post="(MS). Systemic intravenous (IV) doses of BIIB033 up to"/>
  <result pre="nerve fiber layer thickness and disability in different phases of" exact="multiple sclerosis" post="C Uzunköprü 1, N Yuceyar 1, D Taskiran 2,"/>
  <result pre="candidate to be a reliable biomarker of axonal degeneration in" exact="multiple sclerosis" post="(MS).The measurement of retinal nerve fiber layer (RNFL) has"/>
  <result pre="higher levels of both biomarkers than RRMS(p&amp;lt; 0,05) Irrespective of" exact="optic neuritis" post="history, all MS patients exhibited significantly lower RNFL thickness"/>
  <result pre="MS. P264 Correlation of mRNA expression in the blood with" exact="multiple sclerosis" post="disease activity on MRI JW Lindsey 1, EY Lu"/>
  <result pre="Background: Exacerbations or relapses are a typical clinical feature of" exact="multiple sclerosis" post="(MS). Some relapses follow infections, but most occur without"/>
  <result pre="MS activity will differ widely between individuals. P265 Identification of" exact="multiple sclerosis" post="cerebrospinal fluid biomarkers using nuclear magnetic resonance spectroscopy MA"/>
  <result pre="small molecular weight present in cerebrospinal fluid (CSF). Diagnosis of" exact="multiple sclerosis" post="(MS) and clinically isolated syndrome (CIS) is based on"/>
  <result pre="sequencing of microRNA in the CD4+ T-cells of secondary progressive" exact="multiple sclerosis" post="individuals KA Sanders 1,2, RA Lea 2, SE Agland"/>
  <result pre="Genetics, Newcastle, Australia Background: The role of microRNAs (miRNA) in" exact="multiple sclerosis" post="extends beyond their use as biomarkers for diagnosis and"/>
  <result pre="mechanisms in MS progression. P267 MicroRNA-572 expression in serum of" exact="multiple sclerosis" post="patients with different patterns of disease progression S Agostini"/>
  <result pre="Foundation, Lab Molecular Medicine, Milano, Italy Background: Clinical progression of" exact="multiple sclerosis" post="(MS) is correlated to accumulation of impairment due to"/>
  <result pre="biomarker for remyelination. P268 Uric acid levels are reduced in" exact="multiple sclerosis" post="M Moccia 1, R Lanzillo 1, R Palladino 2,3,"/>
  <result pre="by means of gene expression profiling in patients with progressive" exact="multiple sclerosis" post="R Nurtdinov 1, C Tur 1, S Malhotra 1,"/>
  <result pre="in patients with clinically isolated syndromes (CIS) who convert to" exact="multiple sclerosis" post="(MS) in comparison to those who remain as CIS."/>
  <result pre="Sendai, Japan Background: Neuromyelitis optica (NMO) is characterized by severe" exact="optic neuritis" post="and transverse myelitis. The extensive loss of AQP4 and"/>
  <result pre="astrocytic destructive damages. CSF-GFAP level itself in the relapse of" exact="optic neuritis" post="in NMOsd is relatively low prevalence than cerebral lesion"/>
  <result pre="low levels of phosphatidylcholines and sphingomyelins in cerebrospinal fluid of" exact="multiple sclerosis" post="patients D Pieragostino 1,2, M D’Alessandro 1,2, M Di"/>
  <result pre="the molecular mechanisms underlying the disease. P274 Metabolomic profile of" exact="multiple sclerosis" post="patients E Cocco 1, L Lorefice 1, F Murgia"/>
  <result pre="of cerebrospinal fluid reveals a distinctive biochemical alteration associated with" exact="multiple sclerosis" post="M di Ioia 1, D Pieragostino 1, M D’Alessandro"/>
  <result pre="of superoxide anion, antioxidative enzyme activity and oxidative damage in" exact="multiple sclerosis" post="patients during relapse D Obradovic 1, M Jovanovic 1,"/>
  <result pre="one of possible mechanisms of central nervous system damage in" exact="multiple sclerosis" post="(MS). Objectives: It was our aim to investigate free"/>
  <result pre="highlighted the involvement of LCN2 in the murine experimental auto-immune" exact="encephalomyelitis" post="(EAE) model of multiple sclerosis (MS), by showing that"/>
  <result pre="LCN2 in the murine experimental auto-immune encephalomyelitis (EAE) model of" exact="multiple sclerosis" post="(MS), by showing that its expression in the brain"/>
  <result pre="levels at diagnosis were associated with clinical severity in a" exact="multiple sclerosis" post="cohort followed in our clinic. Methods: Normal 0 21"/>
  <result pre="predict a faster disease progression. P279 Expression of miRNAs in" exact="multiple sclerosis" post="cerebrospinal fluid and their relation to MR activity E"/>
  <result pre="effectiveness of natalizumab (NAT) versus fingolimod (FTY) in active relapsing-remitting" exact="multiple sclerosis" post="(RR-MS). Objectives: Aim of our study was to compare"/>
  <result pre="The influence of immunomodulatory treatment on the clinical course of" exact="multiple sclerosis" post="A Kavaliunas 1, L Stawiarz 1, A Glaser 1,"/>
  <result pre="One of the major questions concerning the clinical progression of" exact="multiple sclerosis" post="(MS), still insufficiently elaborated or confirmed, is if it"/>
  <result pre="(GA) has provided a safe and effective treatment option for" exact="multiple sclerosis" post="patients. Decades of study have yielded considerable insight into"/>
  <result pre="investigation is warranted in order to ensure the safety of" exact="multiple sclerosis" post="patients. P283 Rituximab following natalizumab withdrawal in relapsing remitting"/>
  <result pre="sclerosis patients. P283 Rituximab following natalizumab withdrawal in relapsing remitting" exact="multiple sclerosis" post="BE Beaber 1, G Mallari 1, D Le 1,"/>
  <result pre="CA, United States Background: Withdrawal from natalizumab treatment in relapsing-remitting" exact="multiple sclerosis" post="(RRMS) often leads to an increase in disease activity"/>
  <result pre="fingolimod versus interferon beta/glatiramer acetate as second-line therapy in active" exact="multiple sclerosis" post="A He 1, T Spelman 1, V Jokubaitis 2,"/>
  <result pre="fingolimod versus IFN/GA as second-line therapy after on-treatment relapse in" exact="multiple sclerosis." post="Methods: Data was extracted from MSBase, an international observational"/>
  <result pre="sclerosis. Methods: Data was extracted from MSBase, an international observational" exact="multiple sclerosis" post="registry. Patients previously treated with IFN/GA for a minimum"/>
  <result pre="therapy (IFNβ) and long-term disability outcomes in patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS). Methods: A prospective and longitudinal 12-year follow-up study"/>
  <result pre="with active disease. P286 Rituximab in the treatment of secondary-progressive" exact="multiple sclerosis" post="C Perrone 1, I Berriosmorales 1, B Beretich 2,"/>
  <result pre="While mitoxantrone is the only FDA-approved drug to treat secondary-progressive" exact="multiple sclerosis" post="(SPMS), its use is limited by high toxicity. A"/>
  <result pre="is limited by susceptibility of NTZ-treated patients to a serious" exact="viral disease" post="of the central nervous system (CNS) - Progressive Multifocal"/>
  <result pre="efficacy of switch to natalizumab or fingolimod in active relapsing-remitting" exact="multiple sclerosis" post="T Kalincik 1,2, D Horakova 3, T Spelman 2,"/>
  <result pre="outcomes between escalation to natalizumab or fingolimod due to active" exact="multiple sclerosis" post="(MS) on injectable immunomodulatory agents. Methods: Using MSBase, an"/>
  <result pre="Background: Persistence with disease-modifying therapies (DMTs) improves clinical outcomes in" exact="multiple sclerosis" post="(MS). No studies have compared persistence among patients receiving"/>
  <result pre="of brain volume loss in the definition of disease-activity-free in" exact="multiple sclerosis" post="using fingolimod phase 3 data N De Stefano 1,"/>
  <result pre="healthy individuals (HIs) is 0.1-0.3%, whereas in patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS), mean annual BVL is accelerated (0.5-1.35%). However, BVL"/>
  <result pre="trial. P292 A six-year clinical follow-up study of patients with" exact="multiple sclerosis" post="who started natalizumab L Prosperini 1, P Annovazzi 2,"/>
  <result pre="treatment to prevent relapses and accumulation of disability due to" exact="multiple sclerosis" post="(MS), as shown in both pivotal trials and real-life"/>
  <result pre="efficacy of Natalizumab and Fingolimod in the treatment of relapsing-remitting" exact="multiple sclerosis" post="(MS) has been proven in randomized trials. However, such"/>
  <result pre="P294 Comparison of dropout rates of disease modifying therapies in" exact="multiple sclerosis" post="M Kurtuncu 1, S Yildiz Celik 1, A Coban"/>
  <result pre="There is an obvious need for head-to-head treatment studies in" exact="multiple sclerosis" post="(MS). The lack of drug comparison trials may at"/>
  <result pre="RI, United States Background: A robust, up-to-date treatment algorithm for" exact="multiple sclerosis" post="(MS) based on class I evidence has not been"/>
  <result pre="Background: Interferon Beta-1a (IFNB-1a) is routinely prescribed to persons with" exact="multiple sclerosis" post="(PwMS). Clinicians have an option for choosing the needle"/>
  <result pre="needle for IFNB-1a injection. Methods: Twenty patients with relapsing remitting" exact="multiple sclerosis" post="using IFNB-1a with a 25G needle as part of"/>
  <result pre="25G needle when injecting IFNB-1a. P297 Influence of treatments on" exact="multiple sclerosis" post="disability: a cohort study E Cocco 1, C Sardu"/>
  <result pre="efficacy of treosulfan in 21 patients with active secondary progressive" exact="multiple sclerosis" post="after treatment with mitoxantrone A Deiß 1, S Bräuninger"/>
  <result pre="Münster, Germany Background: Immunotherapy of patients with active secondary progressive" exact="multiple sclerosis" post="(SPMS), after having reached the maximal cumulative dose of"/>
  <result pre="a therapeutic challenge. Treosulfan, a well-tolerated alkylating agent approved for" exact="ovarian cancer," post="was previously found to be effective and safe in"/>
  <result pre="adverse events, including urosepsis followed by deep vein thrombosis and" exact="pulmonary embolism" post="in one patient, as well as severe pneumonia requiring"/>
  <result pre="and pulmonary embolism in one patient, as well as severe" exact="pneumonia" post="requiring assisted ventilation in the other. Both patients fully"/>
  <result pre="adverse events leading to dose or interval alterations included leukocytopenia," exact="thrombocytopenia" post="and infections. No haematologic malignancy was observed (mean follow-up"/>
  <result pre="Comparative tolerability and efficacy of dimethyl fumarate and fingolimod in" exact="multiple sclerosis" post="S Cohn 1, R Bermel 2, C Hara 2,"/>
  <result pre="two commonly used oral disease modifying therapies (DMT) for relapsing" exact="multiple sclerosis" post="(MS). Phase 3 clinical trials established the efficacy and"/>
  <result pre="adverse events of high-dose intravenous methylprednisolone for relapse treatment in" exact="multiple sclerosis" post="(FEEL study) I Stavrakaki 1, ELJ Hoogervorst 2, P"/>
  <result pre="for 3-5 days is the mainstay of relapse treatment in" exact="multiple sclerosis" post="(MS). Despite IVMP being generally considered as well tolerated"/>
  <result pre="P303 Safety and efficacy of dimethyl fumarate in patients with" exact="multiple sclerosis" post="- real world experience C Chaves 1, R Ganguly"/>
  <result pre="disease modifying agent (DMA) recently approved to treat relapsing remitting" exact="multiple sclerosis" post="(RRMS). Its safety and efficacy were demonstrated in two"/>
  <result pre="among propensity score matched patients receiving disease modifying therapy for" exact="multiple sclerosis" post="BH Johnson 1, MM Bonafede 1, C Watson 2"/>
  <result pre="Cambridge, MA, United States Background: A recent study conducted using" exact="multiple sclerosis" post="(MS) registry data mainly from Europe found that natalizumab"/>
  <result pre="5Heinrich-Heine University, Department of Neurology, Düsseldorf, Germany Background: Patients with" exact="multiple sclerosis" post="(MS) frequently discontinue treatment with therapy, although beneficial effects"/>
  <result pre="vs. 43.5), mass (11.8 vs. 21.9), pruritus (7.8 vs. 13.0)," exact="urticaria" post="(5.4 vs. 12.3), and swelling (5.3 vs. 19.4). The"/>
  <result pre="Disease modifying therapies (DMTs) are the mainstay treatment in relapsing-remitting" exact="multiple sclerosis" post="(RRMS). Certain DMTs, such as dimethyl fumarate (DMF), interferon"/>
  <result pre="fumarate in a multicenter, open-label study of patients with relapsing" exact="multiple sclerosis" post="EJ Fox 1, A Vasquez 2, W Grainger 3,"/>
  <result pre="Delayed-release dimethyl fumarate (DMF) demonstrated efficacy and safety in relapsing-remitting" exact="multiple sclerosis" post="(MS) in Phase 3 studies. Gastrointestinal (GI) events were"/>
  <result pre="GI events. P310 A novel MIF inhibitor as therapy for" exact="multiple sclerosis" post="and stroke AA Vandenbark 1,2, R Meza-Romero 1, G"/>
  <result pre="A novel MIF inhibitor as therapy for multiple sclerosis and" exact="stroke" post="AA Vandenbark 1,2, R Meza-Romero 1, G Benedek 1,2,"/>
  <result pre="regulator of CD74 that could block MIF effects and treat" exact="multiple sclerosis" post="(MS) and other CNS diseases. Objectives: Identify the CD74-binding"/>
  <result pre="Determine efficacy of DR-α1 constructs for treatment of experimental autoimmune" exact="encephalomyelitis" post="(EAE) and experimental stroke. Methods: DRa1-peptide constructs were produced,"/>
  <result pre="may have the potential to treat subjects with MS and" exact="stroke" post="without need for HLA screening. P311 Strategies to reduce"/>
  <result pre="the United States for the treatment of relapsing forms of" exact="multiple sclerosis" post="(MS). In the Phase 3 DEFINE and CONFIRM studies,"/>
  <result pre="as an add-on therapy is effective in long-term treatment of" exact="multiple sclerosis" post="S Ozakbas 1, B Piri Cinar 2, D Oz"/>
  <result pre="and combination of interferon beta (IFNB) and pulsed methylprednisolone in" exact="multiple sclerosis" post="(MS), but more evidence are needed to establish clinical"/>
  <result pre="interferon beta 1a and glatiramer asetate in patients with relapsing-remitting" exact="multiple sclerosis" post="leads to a significant reduction in relapse rate and"/>
  <result pre="demographics and disease-modifying therapy use in relapsing-remitting and secondary progressive" exact="multiple sclerosis" post="in the United States HJ Gross 1, C Watson"/>
  <result pre="Inc., Cambridge, MA, United States Background: Some patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS) subsequently develop secondary progressive multiple sclerosis (SPMS). While"/>
  <result pre="patients with relapsing-remitting multiple sclerosis (RRMS) subsequently develop secondary progressive" exact="multiple sclerosis" post="(SPMS). While the number of effective treatment options indicated"/>
  <result pre="number of effective treatment options indicated for relapsing forms of" exact="multiple sclerosis" post="(MS) in the United States (US) has increased over"/>
  <result pre="mainly used as second line therapies for patients with relapsing-remitting" exact="multiple sclerosis" post="and insufficient response on first line therapies. No formal"/>
  <result pre="P315 Clinical experience with rituximab in the treatment of refractory" exact="multiple sclerosis" post="F Gascón 1, A Navarré 1, C Alcalá 2,"/>
  <result pre="Background: Rituximab (RTX) is an anti-CD20 monoclonal antibody approved for" exact="rheumatoid arthritis" post="and non-Hodgkin lymphoma that lyses B-cells. Off-label RTX has"/>
  <result pre="Rituximab (RTX) is an anti-CD20 monoclonal antibody approved for rheumatoid" exact="arthritis" post="and non-Hodgkin lymphoma that lyses B-cells. Off-label RTX has"/>
  <result pre="an anti-CD20 monoclonal antibody approved for rheumatoid arthritis and non-Hodgkin" exact="lymphoma" post="that lyses B-cells. Off-label RTX has been used in"/>
  <result pre="autoimmune neurological diseases where B lymphocytes are involved, such as" exact="neuromyelitis optica," post="myasthenia gravis and multiple sclerosis (MS). RTX use in"/>
  <result pre="diseases where B lymphocytes are involved, such as neuromyelitis optica," exact="myasthenia gravis" post="and multiple sclerosis (MS). RTX use in MS has"/>
  <result pre="lymphocytes are involved, such as neuromyelitis optica, myasthenia gravis and" exact="multiple sclerosis" post="(MS). RTX use in MS has been reported to"/>
  <result pre="(21.2%) and 5 mild infections (15.2%). One patient experienced moderate" exact="neutropenia" post="which required RTX withdrawal. Conclusions: In our series RTX"/>
  <result pre="safety and efficacy of fingolimod in clinical practice, experience of" exact="multiple sclerosis" post="health network in Alsace region C Berthe 1, J-C"/>
  <result pre="the first oral therapy for patient with very active relapsing-remitting" exact="multiple sclerosis." post="Objectives: This study gives the first results about Fingolimod"/>
  <result pre="any adverse events (60.0%) including 3 serious adverse events of" exact="macular edema." post="In term of efficiency, FREEDOMS study announced a reduction"/>
  <result pre="and MRI disease activity in young adult patients with relapsing" exact="multiple sclerosis" post="T Chitnis 1, G Karlsson 2, DA Häring 2,"/>
  <result pre="MRI activity have been reported to be higher in younger" exact="multiple sclerosis" post="(MS) patients. To date, no controlled study has been"/>
  <result pre="network meta-analysis of peginterferon beta-1a and injectable therapies for relapsing-remitting" exact="multiple sclerosis" post="K Tolley 1, M Hutchinson 2, A Pachner 3,"/>
  <result pre="or every 4 weeks [Q4W]) has been studied in relapsing-remitting" exact="multiple sclerosis" post="(RRMS) patients in the 2-year Phase 3 ADVANCE trial"/>
  <result pre="beta treatment response with magnetic resonance spectroscopy in relapsing remitiıng" exact="multiple sclerosis" post="MF Yetkin 1, M Mirza 1, H Dönmez 2"/>
  <result pre="black hole and cerebral atrophy burden in Hispanic population with" exact="multiple sclerosis?" post="AR Chinea 1, YG Hernandez 1, ER Estades 1"/>
  <result pre="reported. P321 Challenges experienced by neurologists in the individualization of" exact="multiple sclerosis" post="treatment: findings from an international study SM Hayes 1,"/>
  <result pre="University Hospital, Colchester, United Kingdom Background: The unpredictable nature of" exact="multiple sclerosis" post="(MS) creates several challenges for healthcare providers in the"/>
  <result pre="levels. P322 Fingolimod (Gilenya) confers cognitive stability in active relapsing-remitting" exact="multiple sclerosis" post="patients Y Barak 1,2, D Magalashvili 3, T Paz"/>
  <result pre="efficacy in reducing relapses and delaying disability progression in relapsing-remitting" exact="multiple sclerosis" post="(RRMS) RRMS patients acting as a superagonist to sphingosine-1-phosphate"/>
  <result pre="de Lemos, Spain Background: Fingolimod is a treatment for relapsing-remitting" exact="multiple sclerosis" post="(RRMS). The clinical trials that led to the approval"/>
  <result pre="at another one (x5 normal value). Another side effects were:" exact="macular edema" post="(n=1), self-limited leukopenia (n=7); arterial hypertension (n=2); self-limited liver"/>
  <result pre="normal value). Another side effects were: macular edema (n=1), self-limited" exact="leukopenia" post="(n=7); arterial hypertension (n=2); self-limited liver enzyme elevation (n=2)"/>
  <result pre="patients improved or stabilized). P324 Efficacy of second-line treatments in" exact="multiple sclerosis" post="patients: a multicenter experience in clinical practice R Totaro"/>
  <result pre="second-line treatments (natalizumab and fingolimod) in a cohort of relapsing-remitting" exact="multiple sclerosis" post="(MS) patients completing a treatment period of 12 months"/>
  <result pre="immunomodulatory over immunosuppressive drugs. P326 Spanish Registry of patients with" exact="multiple sclerosis" post="treated with fingolimod (GILENYA Registry): safety and effectiveness after"/>
  <result pre="the follow up period, being only 1 of them serious," exact="second-degree atrioventricular block" post="(0.4%). 1 year after starting treatment with fingolimod, 80.0%"/>
  <result pre="follow up period, being only 1 of them serious, second-degree" exact="atrioventricular block" post="(0.4%). 1 year after starting treatment with fingolimod, 80.0%"/>
  <result pre="follow-up is required. P327 Neurocognitive changes in patients with relapsing-remitting" exact="multiple sclerosis" post="treated with natalizumab N Doehler 1, S Mueller 1,"/>
  <result pre="Pharmacy, Barcelona, Spain Background: Natalizumab is an effective treatment for" exact="multiple sclerosis" post="(MS) patients when administered in 300 mg every 4"/>
  <result pre="300 mg every 4 weeks. However, the incidence of treatment-associated" exact="progressive multifocal leukoencephalopathy" post="(PML) caused by JC virus, compromises this efficacious treatment."/>
  <result pre="treatment. Epidemiology P330 In utero 25-hydroxyvitamin D and risk of" exact="multiple sclerosis" post="among offspring in the Finnish Maternity Cohort K Munger"/>
  <result pre="vitamin D nutrition is associated with a reduced risk of" exact="multiple sclerosis" post="(MS), but whether vitamin D exposure in utero is"/>
  <result pre="cod liver oil use as a vitamin D source and" exact="multiple sclerosis" post="risk in Norway: the EnvIMS study M Cortese 1,2,3,"/>
  <result pre="D level has been associated with an increased risk of" exact="multiple sclerosis." post="It is still unclear whether this suggested effect is"/>
  <result pre="estimates were adjusted for possible confounders such as sun exposure," exact="infectious mononucleosis" post="and smoking. Results: An inverse association was observed for"/>
  <result pre="development of MS. P332 Potential impact of air pollutants on" exact="multiple sclerosis" post="incidence in Tehran, Iran: role of vitamin D P"/>
  <result pre="MS. P333 Temporal effects on the presentation and evolution of" exact="multiple sclerosis" post="KE Harding 1, MD Willis 1, S Loveless 1,"/>
  <result pre="Cardiff, United Kingdom Background: There is evidence that presentation of" exact="multiple sclerosis" post="(MS) is changing, with increasing sex ratios reported in"/>
  <result pre="of mechanisms underlying pathogenesis in MS. P334 The association of" exact="multiple sclerosis" post="prevalence and the soil heavy metal in Isfahan, Iran:"/>
  <result pre="Republic of Background: The steep rising in the number of" exact="multiple sclerosis" post="(MS) patients in Isfahan province, makes this province a"/>
  <result pre="MS risks. P336 Neonatal vitamin D status and risk of" exact="multiple sclerosis" post="P Ueda 1, F Rafatnia 2, M Bäärnhielm 3,"/>
  <result pre="at birth may be associated with risk of adult onset" exact="multiple sclerosis" post="but this link has not been studied directly. Objectives:"/>
  <result pre="relation between 25-hydroxyvitamin D concentration at birth and risk of" exact="multiple sclerosis." post="Methods: This was a population-based case-control study in Sweden"/>
  <result pre="population-based case-control study in Sweden including 459 incident cases of" exact="multiple sclerosis" post="and 663 controls, randomly drawn from a national population"/>
  <result pre="mass spectroscopy method. Using logistic regression, odds ratios for developing" exact="multiple sclerosis" post="were compared between quintiles of neonatal 25-hydroxyvitamin D. Results:"/>
  <result pre="no association between neonatal 25-hydroxyvitamin D quintile and risk of" exact="multiple sclerosis." post="The crude odds ratios for the quintiles, in increasing"/>
  <result pre="index at 20 years of age) as well as ancestry," exact="multiple sclerosis" post="heredity, and socioeconomic group, did not considerably affect the"/>
  <result pre="D status at birth is not associated with risk of" exact="multiple sclerosis" post="at a broad population level, this study provides no"/>
  <result pre="Background: A recent Norwegian study shows an increasing prevalence of" exact="multiple sclerosis" post="(MS) in Norway. The nationwide crude prevalence on 1"/>
  <result pre="play a role. P338 High incidence and increasing prevalence of" exact="multiple sclerosis" post="in British Columbia, Canada: findings from over two decades"/>
  <result pre="validated case definition to estimate the incidence and prevalence of" exact="multiple sclerosis" post="(MS) in BC over a 15 and 20 year"/>
  <result pre="expectancy of women. P339 35 years of mortality due to" exact="multiple sclerosis" post="in Canada, 1975-2009: no decrease in mortality rates despite"/>
  <result pre="Alberta, Edmonton, AB, Canada Background: In the past persons with" exact="multiple sclerosis" post="(MS) died at notably younger ages than the general"/>
  <result pre="Canada Background: Previous studies into seasonal variation of relapses in" exact="multiple sclerosis" post="have had conflicting results. Small relapse numbers, differing diagnostic"/>
  <result pre="with increasing latitudes associated with shorter gaps. P341 Risk of" exact="multiple sclerosis" post="related to month of birth changes over time EG"/>
  <result pre="the changing face of MS hypothesis. P343 The incidence of" exact="multiple sclerosis" post="in New Zealand, 2013: a population- based study S"/>
  <result pre="of Neurology, Christchurch, New Zealand Background: Worldwide, the incidence of" exact="multiple sclerosis" post="(MS) appears to be increasing. Currently there are no"/>
  <result pre="reported prevalence gradient with latitude. P344 Genes and environment in" exact="multiple sclerosis" post="(GEMS) study: enabling the prospective study of individuals at"/>
  <result pre="study: enabling the prospective study of individuals at risk of" exact="multiple sclerosis" post="Z Xia 1,2, L Chibnik 1, A von Korff"/>
  <result pre="currently no reliable tool to guide individualized risk assessment for" exact="multiple sclerosis" post="(MS). Objectives: To test the efficacy of an algorithm"/>
  <result pre="environmental risk score (GERS) that includes 63 genetic variants, sex," exact="infectious mononucleosis" post="(IM), and smoking. We tested the efficacy of GERS"/>
  <result pre="transition from health to disease. P345 Prevalence and incidence of" exact="multiple sclerosis" post="estimated in European Register for Multiple Sclerosis (EUReMS): study"/>
  <result pre="Drulovic, W. Brola, for providing data. P346 Vitamin D in" exact="multiple sclerosis;" post="clinical and immunological implications J Hejgaard Laursen 1, H"/>
  <result pre="Center, Copenhagen, Denmark Background: Vitamin D insufficiency is common among" exact="multiple sclerosis" post="(MS) patients, and hypovitaminosis D has been associated with"/>
  <result pre="of wGRS on familial aggregation and clinical phenotypes in Italian" exact="multiple sclerosis" post="patients F Esposito 1,2, C Guaschino 1,2, L Ferrè"/>
  <result pre="in the past decades as potential risk factors for developing" exact="multiple sclerosis" post="(MS). Pediatric MS offers a unique opportunity to study"/>
  <result pre="of pediatric MS. P349 Increasing prevalence and stable incidence of" exact="multiple sclerosis" post="in Western Norway, 1953-2013 N Grytten 1, JH Aarseth"/>
  <result pre="Hordaland County, Western Norway is a high risk area for" exact="multiple sclerosis" post="(MS). Follow-up studies have suggested a rising prevalence although"/>
  <result pre="has many implications for healthcare services. P351 Sodium intake in" exact="multiple sclerosis" post="patients MF Farez 1, MP Fiol 1, MI Gaitán"/>
  <result pre="in spot urine samples from a cohort of 70 relapsing-remitting" exact="multiple sclerosis" post="patients using Tanaka’s equation. The effect of sodium intake"/>
  <result pre="D status modify the response to vitamin D supplementation in" exact="multiple sclerosis" post="patients and healthy controls P Bhargava 1, SU Steele"/>
  <result pre="Background: While vitamin D insufficiency is a risk factor for" exact="multiple sclerosis" post="(MS), it is common in the general population. Since"/>
  <result pre="may be required based on these variables. P353 Epidemiology of" exact="multiple sclerosis" post="in the Republic of Moldova: an incidence and prevalence"/>
  <result pre="(EUReMS), EAHC Second Health programme 2008-13. P354 Increasing incidence of" exact="multiple sclerosis" post="among women in Buenos Aires: a 21-year health maintenance"/>
  <result pre="Argentina, 2Hospital Italiano, Buenos Aires, Argentina Background: Epidemiological studies in" exact="multiple sclerosis" post="(MS) suggest a trend of increasing disease prevalence and"/>
  <result pre="populations and mainly a disproportional increase in the incidence of" exact="multiple sclerosis" post="in women. The reasons for this are unclear and"/>
  <result pre="Institute, Milan, Italy Background: Multiple sclerosis (MS) is a demyelinating" exact="autoimmune disease" post="influenced by a combination of genetic and environmental factors."/>
  <result pre="of MS-associated variants. P356 The use of valproic acid and" exact="multiple sclerosis" post="NM Nielsen 1, H Svanström 1, E Stenager 2,3,4,"/>
  <result pre="deacetylase (HDAC) might have a beneficial effect on experimental allergic" exact="encephalomyelitis" post="(a murine model of multiple sclerosis). Valproic acid (VPA),"/>
  <result pre="antibody titers against Epstein-Barr virus and human herpesvirus 6 in" exact="multiple sclerosis" post="patients: a one-year follow-up study I Ortega-Madueño 1, L"/>
  <result pre="years, altered levels of vitamin D have been associated with" exact="multiple sclerosis" post="(MS). Objectives: To evaluate the possible association between the"/>
  <result pre="studies will be needed to confirm these results. P358 Early-onset" exact="multiple sclerosis" post="in Isfahan, Iran: a report of the demographic and"/>
  <result pre="of differential diagnosis of MS during childhood. P359 Using patient-derived" exact="multiple sclerosis" post="severity score to demonstrate differences in MS severity across"/>
  <result pre="course was observed in AA men. P360 Disease progression in" exact="multiple sclerosis" post="after age 65 E Leray 1,2, M Genevray 3,"/>
  <result pre="Infectious Diseases Department, Paris, France Background: Age at onset of" exact="multiple sclerosis" post="(MS) is known to be associated with both disease"/>
  <result pre="65. P361 Age at disease onset in familial and sporadic" exact="multiple sclerosis" post="in Argentina JI Rojas 1, L Patrucco 1, J"/>
  <result pre="neurological diseases in which genetic inheritance has a role. In" exact="multiple sclerosis" post="(MS), some population studies found an anticipation of age"/>
  <result pre="anticipation of age at onset in younger generations of familial" exact="multiple sclerosis" post="(FMS) vs. sporadic MS (SMS) in Argentina. Methods: this"/>
  <result pre="D deficiency has been associated with several autoimmune conditions including" exact="multiple sclerosis" post="(MS), and occurs more frequently in regions of high"/>
  <result pre="D in Scotland. P363 Prevalence, demographics and clinical characteristics of" exact="multiple sclerosis" post="in the city of Tlemcen, Algeria Z Barka Bedrane"/>
  <result pre="studies have indicated that Algeria is a low-risk zone for" exact="multiple sclerosis" post="(MS). Objectives: Our objective were to determine the prevalence,"/>
  <result pre="P364 Large scale epidemiological survey of disability progression in Japanese" exact="multiple sclerosis" post="patients I Nakashima 1, N Harada 2, F Nakaya"/>
  <result pre="on the disability status and progression in Japanese patients with" exact="multiple sclerosis" post="(MS) has not been well established. Kumar et al."/>
  <result pre="treatment may slow the progression of MS. P365 Highly active" exact="multiple sclerosis" post="and Epstein-Barr virus reactivation MM Paz Soldan 1, EP"/>
  <result pre="Clinic, Neurology, Rochester, MN, United States Background: Risk of developing" exact="multiple sclerosis" post="(MS) has been associated with an expanding number of"/>
  <result pre="reports. P366 Residential distance from main roads, air pollution, and" exact="multiple sclerosis" post="disability in Southern California L Amezcua 1, V Chat"/>
  <result pre="United States Background: CNS inflammation and axonal degeneration contribute to" exact="multiple sclerosis" post="(MS)-related disability. Air pollution has been reported to be"/>
  <result pre="VA, United States Background: Identification of modifiable risk factors for" exact="multiple sclerosis" post="is ongoing. Exposure to some of these risk factors"/>
  <result pre="regardless of age of onset. In regression models, race and" exact="obesity" post="were independent predictors of vitamin D status. The prevalence"/>
  <result pre="were independent predictors of vitamin D status. The prevalence of" exact="obesity" post="was significantly higher in the childhood-onset cohort (CO=58.5%; Y-AO=31%;"/>
  <result pre="to vitamin D status in demyelinating disease. Both race and" exact="obesity" post="are independent factors impacting vitamin D insufficiency/deficiency, regardless of"/>
  <result pre="and may have a role in the development of childhood-onset" exact="multiple sclerosis." post="P368 Vitamin D level and its clinical correlation in"/>
  <result pre="of vitamin D was one of the risk factor for" exact="multiple sclerosis" post="(MS). Moreover, some reported found that replacement vitamin D"/>
  <result pre="other demyelinating diseases such as Clinical Isolated Syndrome (CIS) or" exact="neuromyelitis optica" post="(NMO)/NMO spectrum disorders (NMOSDs). Objectives: To evaluate vitamin D"/>
  <result pre="with degree of disability in patients with fully ambulatory relapsing-remitting" exact="multiple sclerosis" post="E Thouvenot 1,2, M Orsini 3, J-P Daures 3,"/>
  <result pre="Background: Vitamin D deficiency is a recognized risk factor for" exact="multiple sclerosis" post="(MS) and is associated with increased disease activity. It"/>
  <result pre="University of Copenhagen, Neurology, Glostrup, Denmark Background: The aetiology of" exact="multiple sclerosis" post="(MS) is complex, both genetic traits and environmental factors"/>
  <result pre="(EDSS=6). The most common symptom was numbness (58%) followed by" exact="optic neuritis" post="(16%). Patients treated with a DMT were only half"/>
  <result pre="benign in most patients. P373 Specific clinical phenotypes of relapsing" exact="multiple sclerosis" post="based on disease activity EJ Gettings 1, CT Hackett"/>
  <result pre="patterns. Objectives: To identify and characterize clinical phenotypes of relapsing" exact="multiple sclerosis" post="(MS) in a longitudinally designed retrospective study. We aimed"/>
  <result pre="Sclerosis (MS) is classically considered as a T lymphocyte- mediated" exact="autoimmune disease." post="However, the efficacy of therapies targeting B cells and"/>
  <result pre="made use of a genetically determined model of experimental autoimmune" exact="encephalomyelitis" post="in transgenic mice harboring MOG specific T and B"/>
  <result pre="autoimmunity. P376 Serpine1 is a negative regulator of experimental autoimmune" exact="encephalomyelitis" post="M Rangachari 1, N Boivin 1, A Chen 2,"/>
  <result pre="expression, has been linked genetically to the increased incidence of" exact="multiple sclerosis" post="(MS). These findings suggest that Serpine1 can repress central"/>
  <result pre="Caen, France Background: Today MR diagnosis and therapeutic assessment of" exact="multiple sclerosis" post="(MS) is only based on quantification of contrast-enhancing lesions"/>
  <result pre="and prevents disease progression in a humanized mouse model of" exact="multiple sclerosis" post="D Graham 1, S Huang 1, J-K Choi 2,"/>
  <result pre="myelin basic protein (MBP), selected based on immunodominant epitopes in" exact="multiple sclerosis" post="(MS) patients with human leukocyte antigen (HLA) haplotypes DRB1*1501"/>
  <result pre="a new therapeutic under investigation in clinical trials. Experimental autoimmune" exact="encephalomyelitis" post="(EAE) induced in humanized mice engineered to express the"/>
  <result pre="Astrocyte CCL2 sustains immune cell infiltration in chronic experimental autoimmune" exact="encephalomyelitis" post="R Kim 1, N Itoh 1, A Hoffman 1,"/>
  <result pre="function in vivo during disease in the most widely used" exact="multiple sclerosis" post="model, experimental autoimmune encephalomyelitis (EAE), is not known ."/>
  <result pre="in the most widely used multiple sclerosis model, experimental autoimmune" exact="encephalomyelitis" post="(EAE), is not known . Objectives: Determine the role"/>
  <result pre="short chain fatty acids on the course of experimental autoimmune" exact="encephalomyelitis" post="A Haghikia 1, A Duscha 1, J Berg 1,"/>
  <result pre="Background: Despite new insights into the genetics and epigenetics of" exact="multiple sclerosis" post="(MS) its etiology, in particular the role that the"/>
  <result pre="particular propionic acid (PA) on the course of experimental autoimmune" exact="encephalomyelitis" post="(EAE). Methods: MOG-immunized C57/Bl6-mice were either treated with PA"/>
  <result pre="properties that is being developed for the treatment of relapsing-remitting" exact="multiple sclerosis" post="(RRMS) and other inflammatory and neurodegenerative diseases. In two"/>
  <result pre="progression. P382 Oxysterols regulate T lymphocytes trafficking during experimental autoimmune" exact="encephalomyelitis" post="F Chalmin 1, V Rochemont 1, C Lippens 1,"/>
  <result pre="oxysterols and of Ch25h in the pathogenesis of experimental autoimmune" exact="encephalomyelitis" post="(EAE), an animal model of multiple sclerosis and to"/>
  <result pre="pathogenesis of experimental autoimmune encephalomyelitis (EAE), an animal model of" exact="multiple sclerosis" post="and to investigate the underlying mechanisms. Methods: EAE model"/>
  <result pre="disease severity and cognitive impairment especially in later stages of" exact="multiple sclerosis" post="(MS), they can be hardly detected by conventional MRI."/>
  <result pre="potent activator of the Nurr1 signaling pathway, on experimental autoimmune" exact="encephalomyelitis" post="in mouse F Montarolo 1, C Raffaele 2, S"/>
  <result pre="Discovery Chemistry, Basel, Switzerland Background: Multiple sclerosis (MS) is an" exact="autoimmune disease" post="affecting central nervous system, in which Th1/Th17 cells are"/>
  <result pre="1-phosphate (S1P), a lysophospholipid, was shown to be relevant to" exact="multiple sclerosis" post="(MS) therapeutics through oral fingolimod (FTY720), an S1P analog"/>
  <result pre="of Neurology, Sendai, Japan Background: Neuromyelitis optica (NMO) is an" exact="autoimmune disease" post="associated with NMO-IgG, which targets aquaporin 4 (AQP4) mainly"/>
  <result pre="P387 Laquinimod prevents NMOIg-induced disease exacerbation in a model of" exact="neuromyelitis optica" post="AT Argaw 1,2,3, L Asp 1,2,3, J Zhang 1,2,3,"/>
  <result pre="the immunomodulator laquinimod, currently in a Phase 3 trial for" exact="multiple sclerosis," post="restricts NMOIg CNS entry and exacerbation of neuropathology and"/>
  <result pre="of an anti-mouse CD52 antibody (anti-muCD52) in an experimental autoimmune" exact="encephalomyelitis" post="(EAE) mouse model has allowed for further characterization of"/>
  <result pre="effects of anti-muCD52 treatment in an EAE mouse model of" exact="multiple sclerosis" post="(MS) to provide a better understanding of the mechanism"/>
  <result pre="an important correlate to clinical disability and disease duration in" exact="multiple sclerosis" post="(MS). Gray matter atrophy in the cerebral cortex has"/>
  <result pre="cerebral cortex has been shown by MRI in experimental autoimmune" exact="encephalomyelitis" post="(EAE), the most widely used model of MS. The"/>
  <result pre="administered after disease onset. P390 Chondroitin 6-O-sulfate ameliorates experimental autoimmune" exact="encephalomyelitis" post="K Miyamoto 1, R Ueno 1, K Kadomatsu 2,"/>
  <result pre="6-O-sulfate transferase 1-deficient (C6st1 −/−) mice were induced experimental autoimmune" exact="encephalomyelitis" post="(EAE) . C6ST1 is the enzyme that transfers sulfate"/>
  <result pre="be a novel therapeutic strategy for neuroimmunological diseases such as" exact="multiple sclerosis." post="P391 Adaptive angioplasticity promotes recovery in experimental autoimmune encephalomyelitis"/>
  <result pre="multiple sclerosis. P391 Adaptive angioplasticity promotes recovery in experimental autoimmune" exact="encephalomyelitis" post="N Esen 1, P Dore-Duffy 1 1Wayne State University,"/>
  <result pre="conditioning). We hypothesize that adaptive angioplasticity will ameliorate experimental autoimmune" exact="encephalomyelitis" post="(EAE) in mice through a Hypoxia Inducible Factor-1alpha (HIF-1a)/HIF-2a-dependent"/>
  <result pre="effect of adaptive angioplasty in a neurodegenerative disease model of" exact="multiple sclerosis" post="(MS). Methods: C57BL/6 mice were immunized with MOG35-55 peptide."/>
  <result pre="(MRI) correlates strongly with disease duration and clinical disability in" exact="multiple sclerosis" post="(MS). However, the mechanisms underlying gray matter atrophy remain"/>
  <result pre="cerebral cortex has been shown by MRI in experimental autoimmune" exact="encephalomyelitis" post="(EAE), the most widely used model of MS. Objectives:"/>
  <result pre="GA treatment on mitochondrial dynamics and biogenesis in experimental allergic" exact="encephalomyelitis" post="(EAE), an animal model for MS. Methods: EAE was"/>
  <result pre="of GA but also provide a good target to prevent" exact="neurodegeneration" post="in EAE and MS. P394 Superior efficacy of glucocorticoid"/>
  <result pre="MS. P394 Superior efficacy of glucocorticoid treatment of experimental autoimmune" exact="encephalomyelitis" post="in macrophage migration inhibitory factor deficient mice N Ji"/>
  <result pre="effects. GCs are the standard treatment for acute attacks of" exact="multiple sclerosis" post="(MS), however, they eventually lose efficacy and overall do"/>
  <result pre="a role in resistance to GC treatment using experimental autoimmune" exact="encephalomyelitis" post="(EAE), a common animal model of MS. Methods: We"/>
  <result pre="both the brains of Wt and MIF-/- mice; however, the" exact="suppression" post="lasted longer in MIF-/- mice once the treatment was"/>
  <result pre="reduces disease severity in a mouse model of experimental autoimmune" exact="encephalomyelitis" post="S-K Kim 1, J Kassis 1, O Attucks 1,"/>
  <result pre="mice confers cytoprotection against spinal cord injury and experimental autoimmune" exact="encephalomyelitis" post="(EAE). We therefore designed potent and specific inhibitors of"/>
  <result pre="of critical importance in a range of experimental conditions including" exact="obesity" post="and autoimmunity. The functional properties of GALT derived regulatory"/>
  <result pre="including CCL22 and CXCL13. In separate experiments, e xperimental autoimmune" exact="encephalomyelitis" post="(EAE) was induced in SJL/J mice with proteolipid protein"/>
  <result pre="and mechanisms of antigen-specific tolerogenic dendritic cells in experimental autoimmune" exact="encephalomyelitis" post="MJ Mansilla 1, S Fabregas 1, J Navarro 1,"/>
  <result pre="attenuation of pathogenic T cells in autoimmune diseases such as" exact="multiple sclerosis" post="(MS). Objectives: To compare the therapeutic effect of antigen-specific"/>
  <result pre="unloaded TolDCs in the animal model of MS, experimental autoimmune" exact="encephalomyelitis" post="(EAE). Methods: Bone marrow (BM) cells from C57BL/6 mice"/>
  <result pre="axon circuit alterations in a chronic demyelinating mouse model of" exact="multiple sclerosis" post="N Harris 1, A Khalaj 2, R Mofrad-Babapour 2,"/>
  <result pre="Riverside, CA, United States Background: Unlike autoimmune demyelinating pathology in" exact="multiple sclerosis" post="(MS) and experimental autoimmune encephalomyelitis (EAE) mice, cuprizone (CPZ)"/>
  <result pre="autoimmune demyelinating pathology in multiple sclerosis (MS) and experimental autoimmune" exact="encephalomyelitis" post="(EAE) mice, cuprizone (CPZ) diet-induced demyelination and normal diet-induced"/>
  <result pre="reveal optic nerve involvement in a relapsing remitting model of" exact="multiple sclerosis" post="R Santangelo 1, V Castoldi 1, L Camaleonti 1,"/>
  <result pre="Spectroscopic determination of chelating properties and uptake in the cuprizone" exact="multiple sclerosis" post="model AA Taraboletti 1, JA Caporoso 1, H Huang"/>
  <result pre="study pathways involved in white matter damage that occurs in" exact="multiple sclerosis" post="(MS). Administration of cuprizone to mice results in reproducible"/>
  <result pre="Brain Research Institute, Zurich, Switzerland Background: The targeted experimental autoimmune" exact="encephalomyelitis" post="(EAE) model in rats is a variant of EAE,"/>
  <result pre="of an experimental MS. P404 Clinical outcome of experimental autoimmune" exact="encephalomyelitis" post="in semaphorin 7A-deficient mice A Gutiérrez-Franco 1, H Eixarch"/>
  <result pre="(CNS) injury. Its role in the pathogenesis of experimental autoimmune" exact="encephalomyelitis" post="(EAE) is controversial. Objectives: We aimed to study the"/>
  <result pre="our current protocol: 50µg of MOG 35-55, 300µg of Mycobacterium" exact="tuberculosis" post="(McT) and 150ng of pertussis toxin (Pt) per mouse."/>
  <result pre="MOG 35-55, 300µg of Mycobacterium tuberculosis (McT) and 150ng of" exact="pertussis" post="toxin (Pt) per mouse. Additionally, different doses of antigen"/>
  <result pre="for EAE outcome. P405 Gender-specific neuregulin1 modulation of experimental autoimmune" exact="encephalomyelitis" post="F Song 1, H Deol 1, J Liu 1,"/>
  <result pre="Background: The mechanisms that modulate disease severity and progression in" exact="multiple sclerosis" post="(MS) are poorly understood and MS is more common"/>
  <result pre="NRG1 antagonist (HBD-S-H4) on myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune" exact="encephalomyelitis" post="(EAE). Methods: HBD-S-H4 is a novel humanized fusion protein"/>
  <result pre="protect against optic nerve degeneration in an experimental model of" exact="multiple sclerosis" post="C Cordova 1, B Gutierrez 2, R Martin 3,"/>
  <result pre="Optic neuritis (ON) is a frequent and early symptom of" exact="multiple sclerosis" post="(MS). ON is a condition involving inflammation, oxidative stress,"/>
  <result pre="visual loss. Currently, ON has no effective treatment. Experimental autoimmune" exact="encephalomyelitis" post="(EAE) is the animal model used to study MS"/>
  <result pre="injury. Therefore OA may be a therapeutic strategy for suppressing" exact="neurodegeneration" post="in optic neuritis. P407 Relative protection of H. pylori"/>
  <result pre="OA may be a therapeutic strategy for suppressing neurodegeneration in" exact="optic neuritis." post="P407 Relative protection of H. pylori sonicate administration against"/>
  <result pre="of epidemiological correlation between Helicobacter Pylori ( Hp) infection and" exact="multiple sclerosis" post="(MS). However, experimental evidence on the field is lacking."/>
  <result pre="compared to the PBS-treated group, upon induction of experimental autoimmune" exact="encephalomyelitis" post="(EAE), through immunization with MOG 35-55 peptide (mean EAE"/>
  <result pre="is sufficient to drive neuro-inflammation in an animal model of" exact="multiple sclerosis" post="CR Parker 1, AS Archambault 1, J Sim 2,"/>
  <result pre="cells are increasingly regarded as integral to the pathogenesis of" exact="multiple sclerosis" post="(MS). The mechanisms by which B cells participate in"/>
  <result pre="support disease in the animal model of MS, experimental autoimmune" exact="encephalomyelitis" post="(EAE). However, due to the indirect clinical evidence for"/>
  <result pre="APC function during the initiation and propagation of experimental autoimmune" exact="encephalomyelitis" post="(EAE). In particular, we aimed to examine the role"/>
  <result pre="cells (BMCs) transduced with MOG 40-55 peptide into experimental autoimmune" exact="encephalomyelitis" post="(EAE) mice improved the disease. We also reported that"/>
  <result pre="by neuronal cells under physiological conditions, has been implicated in" exact="cerebellar ataxia" post="and schizophrenia. Although its relative TGM2 has been found"/>
  <result pre="differentiation and inflammation, the involvement of TGM6 in EAE and" exact="multiple sclerosis" post="is still unknown. Objectives: To investigate TGM6 in murine"/>
  <result pre="induced in C57BL6 mice by MOG 35-55/CFA immunization followed by" exact="pertussis" post="toxin injections (at 0 and 48h post immunization). Animals"/>
  <result pre="loci for anti-EBNA-1 IgG titres are associated with risk of" exact="multiple sclerosis" post="Y Zhou 1, G Zhu 2, DR Nyholt 2,"/>
  <result pre="infection with EBV is associated with an increased risk of" exact="multiple sclerosis" post="(MS). Objectives: To identify genetic susceptibility loci for EBV"/>
  <result pre="NcoI polymorphism is associated with inflammatory and metabolic markers in" exact="multiple sclerosis" post="patients AP Kallaur 1, SR Oliveira 1, PRVP Rodrigues"/>
  <result pre="a pro-inflammatory cytokine that might induce the inflammatory process in" exact="multiple sclerosis" post="(MS) patients and results in high disability levels and"/>
  <result pre="incidence and severity. P414 Impact of genetic risk loci in" exact="multiple sclerosis" post="on expression of proximal genes T James 1, M"/>
  <result pre="Medicine, Stockholm, Sweden Background: The major genetic susceptibility factors for" exact="multiple sclerosis" post="(MS) are different alleles in the HLA-DRB1 and HLA-A"/>
  <result pre="Department of Neurology, Bochum, Germany Background: The genetic basis of" exact="multiple sclerosis" post="(MS) as a multifactorial disease was underscored by the"/>
  <result pre="variation study identified T-cell receptor as a susceptibility gene for" exact="multiple sclerosis" post="and neuromyelitis optica S Sato 1, K Yamamoto 2,"/>
  <result pre="T-cell receptor as a susceptibility gene for multiple sclerosis and" exact="neuromyelitis optica" post="S Sato 1, K Yamamoto 2, T Matsushita 1,"/>
  <result pre="in several diseases, the effect of CNVs on susceptibility to" exact="multiple sclerosis" post="(MS) and neuromyelitis optica (NMO) is unknown. Objectives: To"/>
  <result pre="effect of CNVs on susceptibility to multiple sclerosis (MS) and" exact="neuromyelitis optica" post="(NMO) is unknown. Objectives: To identify CNVs associated with"/>
  <result pre="patients with MS and NMO. P417 Genetic interaction analysis of" exact="multiple sclerosis" post="risk loci M Lindén 1, I Lima Bomfim 1,"/>
  <result pre="Environmental Medicine, Stockholm, Sweden Background: The sibling recurrence risk for" exact="multiple sclerosis" post="(MS) is estimated to be 7.1. The major genetic"/>
  <result pre="Groningen, Netherlands Background: In the recent IMSGC collaborative study 110" exact="multiple sclerosis" post="(MS) risk loci have been established which, next to"/>
  <result pre="These results support the previous studies. P419 Susceptibility variants for" exact="multiple sclerosis" post="in the Japanese population T Matsushita 1, S Sato"/>
  <result pre="people of Japanese and European descent. P420 Genetic predictors of" exact="multiple sclerosis" post="G Disanto 1, R Dobson 2, J Pakpoor 3,"/>
  <result pre="investigate the genetic and environmental architecture of immune variation in" exact="multiple sclerosis" post="PA Winn 1, M Cimpean 1, A Robbins 1,"/>
  <result pre="Multiple genetic as well as environmental factors influence susceptibility to" exact="multiple sclerosis" post="(MS). These genetic risk factors are common in the"/>
  <result pre="their receptors modulate IFN-γ and TNF-α associations with relapse in" exact="multiple sclerosis" post="Y Zhou 1, BV Taylor 1, N Stewart 1,"/>
  <result pre="mononuclear cells (PBMC) production of cytokines have been found in" exact="multiple sclerosis" post="(MS) compared to healthy controls. We have previously found"/>
  <result pre="and plasma concentration of IL-18 and IL-36 in relapsing remitting" exact="multiple sclerosis" post="patients F Khosravian 1, M Azadi 1, F Alsahebfosoul"/>
  <result pre="that cytokines play an important role in the pathogenesis of" exact="multiple sclerosis" post="(MS). Here we will focus on two of the"/>
  <result pre="control group. Methods: 105 Iranian patients that clinically definite as" exact="multiple sclerosis" post="(RRM) and 113 healthy controls were enrolled. IL-18 gene"/>
  <result pre="All selected patients were clinically diagnosed as having relapsing remitting" exact="multiple sclerosis" post="(RRMS) .The plasma levels of the cytokines IL-36 and"/>
  <result pre="imaging findings in healthy, genetically characterized, asymptomatic first-degree relatives of" exact="multiple sclerosis" post="patients SU Steele 1, AC Bakshi 1, Z Xia"/>
  <result pre="lesions precede the onset of clinical signs and symptoms in" exact="multiple sclerosis" post="(MS). Identification of a subset of first-degree relatives at"/>
  <result pre="of neurological disability. P426 Target resequencing of regions associated with" exact="multiple sclerosis" post="in the Italian population N Barizzone 1, S Anand"/>
  <result pre="P427 Human Aquaporin 4 gene polymorphisms in Chinese patients with" exact="neuromyelitis optica" post="spectrum disorders W Qiu 1, Y Chang 1, R"/>
  <result pre="(AQP4) and anti-AQP4 autoantibodies（NMO-IgG） are involved in the pathogenesis of" exact="neuromyelitis optica" post="(NMO) and neuromyelitis optica spectrum disorders (NMOSD). Conflicting results"/>
  <result pre="are involved in the pathogenesis of neuromyelitis optica (NMO) and" exact="neuromyelitis optica" post="spectrum disorders (NMOSD). Conflicting results have been reported regarding"/>
  <result pre="Interestingly, DDX39B (BAT1) has also been associated with Myasthenia Gravis," exact="rheumatoid arthritis" post="and systemic lupus. Analyses of naïve CD4+ T cells"/>
  <result pre="DDX39B (BAT1) has also been associated with Myasthenia Gravis, rheumatoid" exact="arthritis" post="and systemic lupus. Analyses of naïve CD4+ T cells"/>
  <result pre="gene variability influences recovery and residual disability after relapses in" exact="multiple sclerosis" post="M Vercellino 1, C Fenoglio 2, C Chiavazza 1,"/>
  <result pre="gray matter (GM) atrophy are related to clinical disability in" exact="multiple sclerosis" post="(MS), but their respective contribution is still debated. Objectives:"/>
  <result pre="debated. Objectives: To investigate WM and GM damage in benign" exact="multiple sclerosis" post="(BMS). Methods: A prospective study included relapsing-remitting MS patients"/>
  <result pre="cord gray matter atrophy with disability and disease type in" exact="multiple sclerosis" post="R Schlaeger 1,2, ND Papinutto 1, C Bevan 1,"/>
  <result pre="and Biomedical Imaging, San Francisco, CA, United States Background: In" exact="multiple sclerosis" post="(MS) cerebral gray matter (GM) atrophy correlates more strongly"/>
  <result pre="is of great interest in many neurodegenerative diseases, such as" exact="multiple sclerosis" post="and Alzheimer’s disease. It is further established that age-related"/>
  <result pre="diffuse structural pathology in the motor network in subjects with" exact="multiple sclerosis" post="(MS). To explore the impact of NE changes on"/>
  <result pre="(WM) injury are the pathological substrate of clinical progression in" exact="multiple sclerosis" post="(MS). The interdependence between these two processes, however, is"/>
  <result pre="Texture of deep gray matter areas relates to disability in" exact="multiple sclerosis" post="L Gaetano 1, S Magon 1, M Chakravarty 2,3,"/>
  <result pre="of Neurology, Basel, Switzerland Background: Brain volume loss (BVL) in" exact="multiple sclerosis" post="(MS) occurs at rates that exceed those reported in"/>
  <result pre="catch up regarding overall brain volume loss. P440 Iron in" exact="multiple sclerosis" post="lesions can be detected by larger volumes on quantitative"/>
  <result pre="Haven, NY, United States Background: A key feature of inflamed" exact="multiple sclerosis" post="lesions is the presence of activated microglia/macrophages (m/M), some"/>
  <result pre="Grey matter abnormalities in mesial temporal lobe characterize patients with" exact="multiple sclerosis" post="and epilepsy M Calabrese 1, NS Orefice 2, M"/>
  <result pre="in mesial temporal lobe characterize patients with multiple sclerosis and" exact="epilepsy" post="M Calabrese 1, NS Orefice 2, M Castellaro 3,"/>
  <result pre="cross-sectional and longitudinal studies we observed that MS patients with" exact="epilepsy" post="had a significant increase in number and volume of"/>
  <result pre="15 patients, 9 reported symptoms that could be ascribed to" exact="temporal lobe epilepsy" post="(such as deja vu, jamais vu or auditory, gustatory"/>
  <result pre="9 reported symptoms that could be ascribed to temporal lobe" exact="epilepsy" post="(such as deja vu, jamais vu or auditory, gustatory"/>
  <result pre="This would be in line with the high frequency of" exact="temporal lobe epilepsy" post="observed in our patients. P442 OASIS and SuBLIME software"/>
  <result pre="be in line with the high frequency of temporal lobe" exact="epilepsy" post="observed in our patients. P442 OASIS and SuBLIME software"/>
  <result pre="can be used to detect lesions in the brains of" exact="multiple sclerosis" post="(MS) patients and is essential for evaluating disease-modifying therapies"/>
  <result pre="long-term demyelination in normal appearing white matter from relapsing remitting" exact="multiple sclerosis" post="IM Vavasour 1, SC Huijskens 2, SM Meyers 2,"/>
  <result pre="generally accumulate over time in the brains of people with" exact="multiple sclerosis" post="(MS), but there is also evidence for on-going pathological"/>
  <result pre="longitudinal studies. P444 Extended cortical lesion determining acute relapses in" exact="multiple sclerosis" post="M Puthenparampil 1, D Poggiali 1, P Perini 1,"/>
  <result pre="SNPSRR, Padova, Italy Background: Cortical lesions can be observed at" exact="multiple sclerosis" post="onset, increase in number and volume over the course"/>
  <result pre="phase-sensitive inversion recovery (PSIR) magnetic resonance imaging sequences. Results: Five" exact="multiple sclerosis" post="patients had acute &quot;cortical relapses&quot; characterized by Wernicke’s aphasia,"/>
  <result pre="sclerosis patients had acute &quot;cortical relapses&quot; characterized by Wernicke’s aphasia," exact="agraphia" post="with acalculia not associated to motor deficit or linguistic"/>
  <result pre="acute onset of left lower limb paroxysmal hypertonia, temporal lobe" exact="status epilepticus" post="with psychotic symptoms mimicking encephalitis. DIR and PSIR disclosed"/>
  <result pre="scanning can be used to image pathological determinants of progressive" exact="multiple sclerosis" post="L Airas 1, E Rissanen 2, M Gardberg 1,"/>
  <result pre="Finland, 2Turku PET Centre, Turku, Finland Background: In secondary progressive" exact="multiple sclerosis" post="(SPMS),there is diffuse smoldering inflammation compartmentalized within the central"/>
  <result pre="progressive MS. P446 In vivo characterization of axonal damage in" exact="multiple sclerosis" post="using high-gradient diffusion magnetic resonance imaging SY Huang 1,2,"/>
  <result pre="Axonal damage is considered the pathologic substrate of disability in" exact="multiple sclerosis" post="(MS). However, in vivo imaging biomarkers specific for axonal"/>
  <result pre="NAWM. P447 Bi-directional trans-synaptic degeneration in the visual pathway in" exact="multiple sclerosis" post="LJ Balk 1, MD Steenwijk 1, P Tewarie 1,"/>
  <result pre="the different components and for comparing patients with and without" exact="optic neuritis" post="and HC. Results: In patients with MS, an episode"/>
  <result pre="and HC. Results: In patients with MS, an episode of" exact="optic neuritis" post="(MSON) was significantly associated with decreased integrity of the"/>
  <result pre="negatively associated with pRNFL and GCC thickness in patients without" exact="optic neuritis" post="(MSNON). The pRNFL and GCC showed associations with integrity"/>
  <result pre="mechanism. P449 Improved white matter integrity with natalizumab treatment in" exact="multiple sclerosis" post="OT Wiebenga 1,2, MM Schoonheim 2, HE Hulst 2,"/>
  <result pre="atrophy and pathology in connected white matter tracts in long-standing" exact="multiple sclerosis" post="MD Steenwijk 1, M Daams 1,2, PJW Pouwels 3,"/>
  <result pre="Amsterdam, Netherlands Background: Gray matter (GM) atrophy is common in" exact="multiple sclerosis" post="(MS), but the relationship with white matter (WM) pathology"/>
  <result pre="predicted by degree of white matter insult, slows cognition in" exact="multiple sclerosis" post="NA Hubbard 1, MP Turner 1, DM Robinson 2,"/>
  <result pre="within the temporoparietal junction is linked to impaired attention in" exact="multiple sclerosis" post="SM Tobyne 1, D Boratyn 1, J Sherman 1,2,"/>
  <result pre="effortful deployment of attention, a commonly observed cognitive deficit in" exact="multiple sclerosis" post="(MS). Imaging biomarkers of LFC and DFC network integrity"/>
  <result pre="in cerebral deep grey matter is a consistent finding in" exact="multiple sclerosis" post="(MS) while respective results have been controversial in patients"/>
  <result pre="volumetry identifies clinically meaningful atrophy in early relapsing forms of" exact="multiple sclerosis" post="R Opfer 1, A Tewes 1, L Spies 1,"/>
  <result pre="Background: Brain atrophy occurs early and in different subtypes of" exact="multiple sclerosis" post="(MS). Neuro-axonal damage in MS is thought to be"/>
  <result pre="cord area between spinal cord measurements using different coils in" exact="multiple sclerosis" post="patients with 3.0T MRI F-X Aymerich 1, D Pareto"/>
  <result pre="Thalamus structure and function determines severity of cognitive impairment in" exact="multiple sclerosis" post="MM Schoonheim 1, HE Hulst 1, RB Brandt 2,"/>
  <result pre="Center, Neurology, Amsterdam, Netherlands Background: Cognitive impairment is prominent in" exact="multiple sclerosis" post="(MS) and is strongly influenced by thalamic damage. Objectives:"/>
  <result pre="the thalamus explain different severities of cognitive impairment in early" exact="multiple sclerosis." post="Methods: A homogeneous cohort of 157 early MS patients"/>
  <result pre="and function are highly informative regarding overall cognitive performance in" exact="multiple sclerosis." post="Increased thalamic functional connectivity only became apparent in more"/>
  <result pre="tract integrity changes are associated with cognition and disinhibition in" exact="multiple sclerosis" post="HE Hulst 1, RHB Benedict 2, MD Steenwijk 3,"/>
  <result pre="NY, United States Background: Thalamic pathology is frequently found in" exact="multiple sclerosis" post="(MS). These thalamic abnormalities are highly correlated with conversion"/>
  <result pre="MS. P463 Multimodal quantitative magnetic resonance imaging of thalamus in" exact="multiple sclerosis" post="and neuromyelitis optica J Wang 1, Y Liu 2,3,"/>
  <result pre="quantitative magnetic resonance imaging of thalamus in multiple sclerosis and" exact="neuromyelitis optica" post="J Wang 1, Y Liu 2,3, Y Duan 2,"/>
  <result pre="Background: Memory deficits develop in 40-65% of the patients with" exact="multiple sclerosis" post="(MS) and generally lead to problems in daily life"/>
  <result pre="Spain Background: Grey matter pathology is known to occur in" exact="multiple sclerosis" post="(MS) patients early during the disease course. It has"/>
  <result pre="of white matter changes in pediatric monophasic demyelinating disorders and" exact="multiple sclerosis" post="G Longoni 1,2, P Momayyezsiahkal 2, RA Brown 2,"/>
  <result pre="United States Background: In contrast to the multifocal nature of" exact="multiple sclerosis" post="(MS), monophasic acquired demyelinating syndromes (mADS) during childhood may"/>
  <result pre="between pediatric MS and the main mADS presentations (acute disseminated" exact="encephalomyelitis" post="(ADEM), monofocal mADS (mADS m), polyfocal mADS (mADS p),"/>
  <result pre="Background: Chronic black holes (CBHs) indicate irreversible axonal loss in" exact="multiple sclerosis" post="(MS). Objectives: To assess the evolution of gadolinium-enhancing (Gd+)"/>
  <result pre="Ultra-high field MRI of intra- and extra-cellular sodium concentration in" exact="multiple sclerosis" post="M Petracca 1,2, R Teodorescu 1, L Fleysher 3,"/>
  <result pre="Hospitals (UCLH) Biomedical Research Centre, London, United Kingdom Background: In" exact="multiple sclerosis" post="(MS), combined clinical and MRI studies have shown that"/>
  <result pre="the evolution of gadolinium-enhancing (Gd+) lesions into CBHs in relapsing-remitting" exact="multiple sclerosis" post="(RRMS) and secondary progressive multiple sclerosis (SPMS). Methods: The"/>
  <result pre="into CBHs in relapsing-remitting multiple sclerosis (RRMS) and secondary progressive" exact="multiple sclerosis" post="(SPMS). Methods: The PRISMS (RRMS; baseline Expanded Disability Status"/>
  <result pre="P474 Unraveling the neuroimaging markers of motor dysfunction in long-standing" exact="multiple sclerosis" post="M Daams 1,2, MD Steenwijk 1, MP Wattjes 1,"/>
  <result pre="Neurology, Amsterdam, Netherlands Background: Motor dysfunction is well described in" exact="multiple sclerosis" post="(MS) but its pathological substrate is not fully understood."/>
  <result pre="of cortical thickness and cortical lesions with clinical symptoms in" exact="multiple sclerosis" post="K Reuter 1, O Geisseler 1, T Pflugshaupt 1,2,"/>
  <result pre="Institut, Zurich, Switzerland Background: Inflammatory lesions and brain atrophy in" exact="multiple sclerosis" post="(MS) impact the central nervous system white matter as"/>
  <result pre="Bethesda, MD, United States Background: The pathological characteristics of chronic" exact="multiple sclerosis" post="(MS) lesions have been studied extensively. At autopsy, particularly"/>
  <result pre="connectivity of cortical lesions to deep white matter lesions in" exact="multiple sclerosis" post="J-M Tillema 1, S Weigand 2, J Port 3,"/>
  <result pre="a marker and predictor of cognitive function and disability in" exact="multiple sclerosis" post="(MS). Methods: In this longitudinal study, 45 MS patients"/>
  <result pre="P482 Functional and structural connectivity abnormalities underlying clinical disability in" exact="multiple sclerosis" post="E Sbardella 1,2, N Filippi 3, F Tona 1,"/>
  <result pre="matter lesion central veins: an interscanner comparison of patients with" exact="multiple sclerosis" post="and ischemic lesions at 3-Tesla MRI A Samaraweera 1,"/>
  <result pre="3T scanner used. P485 Inflammation does not cause chronic global" exact="neurodegeneration" post="in NMO? A longitudinal multimodel quantitative MRI study comparing"/>
  <result pre="central nervous system lesions are a common feature of both" exact="neuromyelitis optica" post="(NMO) and MS. However accrual of disability in MS"/>
  <result pre="to assess if there is any evidence of progressive, non-lesional" exact="neurodegeneration" post="outside of relapses in NMO as occurs in MS."/>
  <result pre="in MS. If not, this would question the theory that" exact="neurodegeneration" post="occurs as a chronic sequelae to prior inflammatory and"/>
  <result pre="assess whether seropositive NMO is associated with imaging markers of" exact="neurodegeneration" post="over one year. Methods: 18 patients with aquaporin-4 antibody"/>
  <result pre="modalities corroborate to support a lack of non-lesional and progressive" exact="neurodegeneration" post="in NMO, in contrast to MS. The results highlight"/>
  <result pre="of therapies and intervention or track dynamics of disease in" exact="multiple sclerosis" post="(MS). However, to date limited longitudinal data of RS-fMRI"/>
  <result pre="future studies. P487 Functional MRI encoding task for faces in" exact="multiple sclerosis" post="L Vacchi 1, MA Rocca 1,2, GC Riccitelli 1,"/>
  <result pre="associated to poor cognitive outcome. P488 Brain atrophy quantification in" exact="multiple sclerosis" post="S Jain 1, D Smeets 1, DM Sima 1,"/>
  <result pre="the brain has become a standard radiological tool for examining" exact="multiple sclerosis" post="patients. Apart from the presence and location of lesions,"/>
  <result pre="again only with the WM, GM and CSF classes. 20" exact="multiple sclerosis" post="patients participated in a study at VU University Medical"/>
 </snippets>
</snippetsTree>
